



IN THE DISTRICT COURT OF CLEVELAND COUNTY
STATE OF OKLAHOMA

Document split into multiple parts

PART D

STATE OF OKLAHOMA, ex rel.,)
MIKE HUNTER,)
ATTORNEY GENERAL OF OKLAHOMA,)

Plaintiff,)

vs.)

Case No. CJ-2017-816
Judge Thad Balkman

- (1) PURDUE PHARMA L.P.;)
- (2) PURDUE PHARMA, INC.;)
- (3) THE PURDUE FREDERICK COMPANY;)
- (4) TEVA PHARMACEUTICALS USA, INC.;)
- (5) CEPHALON, INC.;)
- (6) JOHNSON & JOHNSON;)
- (7) JANSSEN PHARMACEUTICALS, INC;)
- (8) ORTHO-MCNEIL-JANSSEN)
PHARMACEUTICALS, INC., n/k/a)
JANSSEN PHARMACEUTICALS;)
- (9) JANSSEN PHARMACEUTICA, INC.,)
n/k/a JANSSEN PHARMACEUTICALS, INC.;)
- (10) ALLERGAN, PLC, f/k/a ACTAVIS PLC,)
f/k/a ACTAVIS, INC., f/k/a WATSON)
PHARMACEUTICALS, INC.;)
- (11) WATSON LABORATORIES, INC.;)
- (12) ACTAVIS LLC; and)
- (13) ACTAVIS PHARMA, INC.,)
f/k/a WATSON PHARMA, INC.,)

Defendants.)

STATE OF OKLAHOMA } S.S.
CLEVELAND COUNTY }

FILED

MAY 23 2019

In the office of the
Court Clerk MARILYN WILLIAMS

PRETRIAL CONFERENCE ORDER

S-2325	Letter to James P. Jones from Kathleen Foley re actions taken against Purdue Pharma related to the marketing of OxyContin	PPLPC041000004365	PPLPC041000004367			AU; H; R; PRE; CON; CU; LF; J-MIL-3; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4; T-MIL-10, R	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2326	Q&A Guidance for Oral Discussions - Not for Distribution	PPLPC041000003560	PPLPC041000003561			AU; H; R; PRE; CON; CU; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2327	Purdue - 2010 Public Affairs Plan for Brands and PAP	PPLPC028000275568	PPLPC028000275568			AU; H; R; PRE; CON; CU; LF; J-MIL-3; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4; T-MIL-10, R	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2328	Check copies and Speaker Request Forms	PKY180506543	PKY180506553			AU; H; R; PRE; CON; CU; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2329	www.controlpain-livelifelife.com "Improving health and quality of life" website					AU; H; R; PRE; CON; CU; Not Produced / Cannot Be Located	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2330	Email from Jonathan Sackler re OxyContin	PDD1701459860	PDD1701459868			AU; H; R; PRE; CON; CU; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2331	Partners Against Pain - Continuum of Pain Management	PKY180118611	PKY180118611			First Amendment; AU; H; R; PRE; CON; CU; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2332	Email from Jonathan Sackler re embedded shredder	PDD1715177746	PDD1715177746			AU; H; R; PRE; CON; CU; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2333	Email from Robert Kaiko to Richard Sackler re Oxycontin	PDD1701461372	PDD1701461377			AU; H; R; PRE; CON; CU; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2334	Email from Jonathan Sackler re email matters	PDD1715177710	PDD1715177734			AU; H; R; PRE; CON; CU; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2335	Email from Jonathan Sackler re CR Morphine	PDD1706196946	PDD1706196947			AU; H; R; PRE; CON; CU; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2336	Budgets for Consideration	PPLPC045000008449	PPLPC045000008468			AU; H; R; PRE; CON; CU; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2337	Memo to Distribution from Jonathan D. Sackler re list of people to receive Quarterly Reports	PDD1701827936	PDD1701827936			AU; H; R; PRE; CON; CU; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-2338	Email from Jonathan Sackler re Daily Sales - Last Day of the Month	PDD1706194455	PDD1706194455			AU; H; R; PRE; CON; CU; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2339	Allay patient general fears- Myths & Facts about Opioids	PKY183217894	PKY183217894	PKY183217936		AU; H; R; PRE; CON; CU; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2340	New Drug Application Application for OxContin (oxycodone hydrochloride) Controlled-Release Tablets	PDD8901551906				AU; H; R; PRE; CON; CU	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2341	Interoffice Memorandum to Mortimer, Raymond and Richard Sackler from Michael Friedman re Product Pipeline Strategy	PDD1701029146	PDD1701029146	PDD1701029151		AU; H; R; PRE; CON; CU; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2342	Email from Richard Sackler re Oxycotin Buyin	PDD1706043949	PDD1706043949	PDD1706043950		AU; H; R; PRE; CON; CU; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2343	Email to Dennis Merlo re Start with Stay with	PPLPC028000057006	PPLPC028000057006	PPLPC028000057006		AU; H; R; PRE; CON; CU; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2344	Email from Michael Friedman re Oxycotin Rx data - February 21, 1997	PDD9316706495	PDD9316706495	PDD9316706496		AU; H; R; PRE; CON; CU; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2345	Phase IV Oxycotin Tablets Team Memo to Distribution from E. Ingber/L. Harrison re Phase IV Oxycotin Tablets Team Meeting, Minutes - May 9, 1997	PKY180114479	PKY180114479	PKY180114482		AU; H; R; PRE; CON; CU; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2346	Email from Ricahrd Sackler re 2012 Budget Gross Sales Phasing	PPLPC045000015282	PPLPC045000015282	PPLPC045000015283		AU; H; R; PRE; CON; CU; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2347	Email from Dr. Mortimer Sackler re Greenwich Hospital Purchases	PDD1701806060	PDD1701806060	PDD1701806060		PRE; CON; CU; AU; H; R; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2348	2004 Business Plan - Paul Foster - HSS, Oklahoma	POK003660196				AU; H; R; PRE; CON; CU; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2349	Transcript of Videotaped Deposition of Richard Sackler, MD	PPLP004030482	PPLP004030482	PPLP004030872		R; PRE; CON; CU; AU; H; PRE; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-2350	2006 Update (full) The Underestimated Cost of the Opioid Crisis - The Council of Economic Advisers	PDD8901791203				First Amendment; AU; H; R; PRE; CON; CU; Privileged; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2351	APF and PCF "The Epidemic of Pain in America" (full version)	APF2056				AU; H; R; PRE; CON; CU; J-MIL-12; T-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2352	Declaration of Russell K. Portenoy (full - executed)					Discovery Violations; AU; H; R; PRE; CON; CU; LF; §§ 2401, 2402 PRE; J-MIL-3; J-MIL-6, J-MIL-7; J-MIL-12; J-MIL-14; T-MIL-1; T-MIL-4; T-MIL-9	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2353	Current Concepts in Pain Management	JAN-MS-00323592				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2354	2/16/06 Email from Daniel Keenan to Kati Chupa et al re Duragesic historical sales aids	JAN-MS-00306388				R; PRE; CON; CU; AU; H; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2355	10/10/01 Duragesic 2002 Tactical Plan	JAN-MS-02568390				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2356	Duragesic 2001 Business Plan	JAN-MS-00618253				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2357	1/8/01 Email from Roman to Chupa re Business Plans, attaching 2001 Pain Franchise Plan	JAN-MS-00785750				AU; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901
S-2358	Duragesic Fentanyl Transdermal System 2003 Business Plan July 30, 2002	JAN-MS-00726351				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2359	Duragesic Grow and Defend 2005 Business Plan	JAN-MS-00789137				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2360	Duragesic Production Profile and Timeline	JAN-MS-00779485				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2361	Strategic Customer Group 2003 Business Plan	JAN-MS-03068466				Inadmissible Character Evidence; R; PRE; CON; CU; AU; H; R; LF; J-MIL-3; J-MIL-12; T-MIL-1; PRE	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2362	Duragesic 2003 Business Planning	JAN-MS-00306745				PRE; CON; CU; AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-2364	11/6/01 Email re: Implementing Segmentation, attaching Implementing the Duragesic Segmentation	JAN-MS-00786838				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2365	Duragesic Sales Force Memo, Congratulations to the 500	JAN-MS-00311784				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2366	Duragesic Coupon Program	JAN-MS-00311357				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2367	REMS for Tapentadol ER Training Document	JAN-MS-00986459				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2368	Pain Specialist Background - Opportunities and Challenges	JAN-MS-02757640				R; PRE; CON; CU; AU; H; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2369	3/5/18 Email from Maria Barton to Jonathan Sackler re Research/America	PPLPC039001210550				AU; H; R; PRE; CON; CU; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4; P (This document has been clawedback)	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2370	Federal Register, Volume 73, No. 25, 2/6/2008, pages 6843-6851					AU; H; R; PRE; CON; CU; Incomplete Document; J-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2371	NEO Nonbranded Campaign: Market Research Script March 13, 2008	JAN-MS-00322896				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2372	Responsible Opioid Prescribing CME sponsored by ACS and paid for by J&J and King Pharmaceuticals	JAN-MS-00395275				Judicial Estoppel; R; PRE; CON; CU; AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2373	10/13/99 Memo from Friedman to Mortimer, Raymond and Richard Sackler re: Business Quarterly Report	PPLPC035000002720	PPLPC035000002724			First Amendment; AU; H	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2374	Duragesic Disease Modelling 4	JAN-MS-02339227				AU; H; R; PRE; CON; CU; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2375	Pain Franchise 2012 PR Program	JAN-MS-00405138				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2376	Nucynta Speaker Training October 10, 2012	JAN-MS-00027221				AU; H; SUM; PRE; CU	

S-2377	DEA Drug Scheduling Description and Website (https://www.dea.gov/drug-scheduling)					AU; H; R; PRE; CON; CU; Incomplete Document	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802
S-2378	Drugs of Abuse, DEA Resource Guide, 2017 Ed. (https://www.dea.gov/sites/default/files/drug_of_abuse.pdf)					AU; H; R; PRE; CON; CU; Incomplete Document	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802
S-2379	DEA Early Years Article (https://www.dea.gov/sites/default/files/2018-05/Early%20Years%20p%2012-29.pdf)					AU; H; R; PRE; CON; CU; Incomplete Document	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802
S-2380	DEA Whitepaper - Fentanyl (https://www.dea diversion.usdoj.gov/drug_chem_info/fentanyl.pdf)					AU; H; R; PRE; CON; CU; Incomplete Document; J-MIL-12; T-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802
S-2381	DEA Whitepaper - Hydrocodone (https://www.dea diversion.usdoj.gov/drug_chem_info/hydrocodone.pdf)					AU; H; R; PRE; CON; CU; Incomplete Document; J-MIL-12; T-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802
S-2382	DEA Whitepaper - Oxycodone (https://www.dea diversion.usdoj.gov/drug_chem_info/oxycodone.pdf)					AU; H; R; PRE; CON; CU; Incomplete Document; J-MIL-12; T-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802
S-2383	DEA Whitepaper - Oxymorphone (https://www.dea diversion.usdoj.gov/drug_chem_info/oxymorphone.pdf)					AU; H; R; PRE; CON; CU; Incomplete Document; J-MIL-12; T-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802
S-2384	DEA Whitepaper - Tramadol (https://www.dea diversion.usdoj.gov/drug_chem_info/tramadol.pdf)					AU; H; R; PRE; CON; CU; Incomplete Document; J-MIL-12; T-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802
S-2385	Clinical Overview, Tapentadol ER in the Management of Moderate to Severe Chronic Pain	JAN-MS-00046528				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2386	Management of Opioid Therapy for Chronic Pain, May 2010 Summary Guidelines from Va/DOD	JAN-MS-00014584				First Amendment; H; R	12 O.S. 2401, 2402; 12 O.S. 2802
S-2387	10/7/02 Duragesic Media Planning & Input Form	JAN-MS-00306238&JAN-MS-00306239				First Amendment; R; PRE; CON; CU; AU; H; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802

S-2388	2010 Budget list	JAN-MS-00325975&JAN-MS-00325976				First Amendment; AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2389	IPPC Meeting 4 Output Presentation	JAN-MS-00357584				First Amendment; PRE; CON; CU; AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2390	3/13/09 Email re REMS from Lori Lonczak to Cassie Hallberg	JAN-MS-00589775				First Amendment; AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2391	7/19/11 Email from Frank DeMiro to Gary Vorsanger et al re: Media Alert NYT Well Blog	JAN-MS-00255717				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2392	PAINS Project - First Annual Meeting Sept. 13-15, 2012	PPLPC032000244320	PPLPC032000244382			First Amendment; AU; H; R; PRE; CON; CU; LF; J-MIL-3; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2393	Duragesic GOC Presentation Jan. 21, 2003	JAN-MS-00787764				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2394	2/11/03 Email from Molly McDonald to Kati Chupa et al re: Palladone Message Testing	JAN-MS-00778806				H; PRE; CON; INA; J-MIL #7	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2395	Duragesic "Elita Prescribers" Targeting - Share Recapture, Ascending Share, Constant Share	JAN-MS-00314252				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2396	Continuing Medical Education and the Marketing of Fentanyl for Breakthrough Pain: Marketing Messages in an Industry-Funded CME Module on Breakthrough Pain, Fugh-Berman et al.					AU; H; R; PRE; CON; CU; Incomplete Document; J-MIL-12; T-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2397	Duragesic Journal Advertising Overview March 1991 - Present	JAN-MS-00305469				H; CU; PRE; CON; SUM	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2398	Increase in Unintentional Medication Overdose Deaths, Oklahoma, 1994-2006				2	AU; H; R; PRE; CON; CU; Incomplete Document; SUM; T-MIL-9	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2399	Unintentional Poisoning Deaths in Oklahoma, 2007-2012				3	AU; H; R; PRE; CON; CU; Incomplete Document; SUM; T-MIL-9	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2400	Fatal Unintentional Poisoning Surveillance System: Data Update				4	AU; H; R; PRE; CON; CU; Incomplete Document; SUM; T-MIL-9	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-2401	Oklahoma Special Emphasis Report: Drug Overdose Deaths, 1999-2013								5	AU; H; R; PRE; CON; CU; Incomplete Document; SUM; T-MIL-9	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2402	Opioid Overdoses, Scope of the Epidemic								6	AU; H; R; PRE; CON; CU; SUM; T-MIL-9	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2403	Department of Justice, DEA Arcos 3 - Report 4, CU Distribution by State in Grams per 100,000 population, Reporting Period 01/01/06 to 12/31/06									AU; H; R; SUM; J-MIL-12; T-MIL-1; PRE	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2404	Department of Justice, DEA Arcos 3 - Report 4, CU Distribution by State in Grams per 100,000 population, Reporting Period 01/01/07 to 12/31/07									AU; H; R; SUM; J-MIL-12; T-MIL-1; PRE	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2405	Department of Justice, DEA Arcos 3 - Report 4, CU Distribution by State in Grams per 100,000 population, Reporting Period 01/01/08 to 12/31/08									AU; H; R; SUM; J-MIL-12; T-MIL-1; PRE	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2406	Department of Justice, DEA Arcos 3 - Report 4, CU Distribution by State in Grams per 100,000 population, Reporting Period 01/01/09 to 12/31/09									AU; H; R; SUM; J-MIL-12; T-MIL-1; PRE	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2407	Department of Justice, DEA Arcos 3 - Report 4, CU Distribution by State in Grams per 100,000 population, Reporting Period 01/01/10 to 12/31/10									AU; H; R; SUM; J-MIL-12; T-MIL-1; PRE	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2408	Department of Justice, DEA Arcos 3 - Report 4, CU Distribution by State in Grams per 100,000 population, Reporting Period 01/01/11 to 12/31/11									AU; H; R; SUM; J-MIL-12; T-MIL-1; PRE	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2409	Department of Justice, DEA Arcos 3 - Report 4, CU Distribution by State in Grams per 100,000 population, Reporting Period 01/01/12 to 12/31/12									AU; H; R; SUM; J-MIL-12; T-MIL-1; PRE	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-2410	Department of Justice, DEA Arcos 3 - Report 4, CU Distribution by State in Grams per 100,000 population, Reporting Period 01/01/13 to 12/31/13						AU; H; R; SUM; J-MIL-12; T-MIL-1; PRE	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2411	Department of Justice, DEA Arcos 3 - Report 4, CU Distribution by State in Grams per 100,000 population, Reporting Period 01/01/14 to 12/31/14						AU; H; R; SUM; J-MIL-12; T-MIL-1; PRE	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2412	Department of Justice, DEA Arcos 3 - Report 4, CU Distribution by State in Grams per 100,000 population, Reporting Period 01/01/15 to 12/31/15						AU; H; R; SUM; J-MIL-12; T-MIL-1; PRE	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2413	Department of Justice, DEA Arcos 3 - Report 4, CU Distribution by State in Grams per 100,000 population, Reporting Period 01/01/16 to 12/31/16						AU; H; R; SUM; J-MIL-12; T-MIL-1; PRE	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2414	Department of Justice, DEA Arcos 3 - Report 4, CU Distribution by State in Grams per 100,000 population, Reporting Period 01/01/17 to 12/31/17						AU; H; R; SUM; J-MIL-12; T-MIL-1; PRE	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2415	Annotated Expert Disclosure of Andrew J. Kolodny					Kolodny 1	AU; H; R; PRE; CON; CU; LF; IC; J-MIL-2, J-MIL-3, J-MIL-4; J-MIL-5 J-MIL-6, J-MIL-7, J-MIL-8; J-MIL-9; J-MIL-10; J-MIL-11; J-MIL-12	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2416	Annotated spreadsheet of J&J Corporate Representative Deposition Exhibits					Kolodny 5	AU; H; R; PRE; CON; CU; LF; IC; J-MIL-2, J-MIL-3; J-MIL-4; J-MIL-5; J-MIL-6; J-MIL-7; J-MIL-8; J-MIL-9; J-MIL-10; J-MIL-11	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2417	Annotated spreadsheet of J&J Fact Witness Deposition Exhibits					Kolodny 7	AU; H; R; PRE; CON; CU; LF; IC; J-MIL-2, J-MIL-3; J-MIL-4; J-MIL-5; J-MIL-6; J-MIL-7; J-MIL-8; J-MIL-9; J-MIL-10	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-2418	Annotated Index of Documents for Teva Defendants' Contention Deposition Topics Nos. 2, 3, 4, 10, 13, 14, 16, 34, 37, 38 and Purdue Defendants' Contention Deposition Topic No. 4				Kolodny 3	H; R; AU; LF; J-MIL-2; J-MIL-3; J-MIL-4; J-MIL-5; J-MIL-6; J-MIL-7; J-MIL-8; J-MIL-9	12 O.S. 2401, 2402; 12 O.S. 2802
S-2419	Andrew Kolodny Exhibit 2 Index (Purdue)					R; AU; H; LF; J-MIL-2; J-MIL-3; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4; PRE	12 O.S. 2401, 2402
S-2420	Andrew Kolodny Exhibit 4 Index (J&J)					R; AU; H; LF; J-MIL-2; J-MIL-3; J-MIL-12; T-MIL-1; T-MIL-6; T-MIL-7; T-MIL-8; T-MIL-10, R; PRE	12 O.S. 2401, 2402
S-2421	J&J, Partner of Choice in Pharmaceuticals	JAN-MS-01058448				Inadmissible Character Evidence; R; PRE; CON; CU; AU; H; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2422	CDC Opioid Painkiller Prescribing Infographic (https://www.cdc.gov/vitalsigns/opioid-prescribing/infographic.html)					AU; H; R; PRE; CON; CU; LF; J-MIL-12; T-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2423	Continuing Medical Education Summary - Prepared for deposition of Kimberly Deem-Eshleman on Feb. 5, 2019					H; R	12 O.S. 2401, 2402; 12 O.S. 2802
S-2424	Contributions to Advocacy Organizations Summary - Prepared for deposition of Kimberly Deem-Eshleman on Feb. 5, 2019					H; R	12 O.S. 2401, 2402; 12 O.S. 2802
S-2425	Payment History to KOLs - Prepared for deposition of Kimberly Deem-Eshleman on Jan. 25, 2019					H; R	12 O.S. 2401, 2402; 12 O.S. 2802
S-2426	State Medical Board Members' Beliefs About Pain, Addiction, and Diversion and Abuse: A Changing Regulatory Environment, Gilson et al; Journal of Pain					AU; H; R; PRE; CON; CU; Incomplete Document; LF; J-MIL-12; T-MIL-1; T-MIL-9	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-2427	Continuing Medical Education and the Marketing of Fentanyl for Breakthrough Pain: Marketing Messages in an Industry-Funded CME Module on Breakthrough Pain by Infield, Bell, Waterhouse, Uliassi & Fugh-Berman (http://dx.doi.org/10.1002/wmh3.290)					AU; H; R; PRE; CON; CU; Incomplete Document; LF; J-MIL-12; T-MIL-1; T-MIL-9	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2428	Incidence and Costs of Neonatal Abstinence Syndrom Among Infants with Medicaid 2004-2014 (https://pediatrics.aapublications.org/content/pediatrics/141/4/e20173520.full.pdf)					AU; H; R; PRE; CON; CU; Incomplete Document; LF; J-MIL-12; T-MIL-1; T-MIL-9	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2429	Gilson et al., State Medical Board Members' Beliefs About Pain, Addiction, and Diversion and Abuse: A Changing Regulatory Environment					AU; H; R; PRE; CON; CU; Incomplete Document; LF; J-MIL-12; T-MIL-1; T-MIL-9	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2430	Email from Jonathan Sackler to Craig Landau re 2 populations question	PPLPC039001217179			PPLPC039001217179	AU; H; R; PRE; CON; CU; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2431	Email from Jonathan Sackler to Richard Sackler re Management report card	PPLPC045000012927			PPLPC045000012927	AU; H; R; PRE; CON; CU; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2432	Management Report Card	PPLPC045000012928			PPLPC045000012930	AU; H; R; PRE; CON; CU; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2433	Email to Mortimer Sackler re Opioid Crisis Triggers a Shakedown	PPLPC039001217228			PPLPC039001217233	R; PRE; CON; CU; AU; H; PRE; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2434	Email from Jonathan Sackler re Embedded shredder	PDD1715178025			PDD1715178025	AU; H; R; PRE; CON; CU; LF; J-MIL-7; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2435	Executive Committee Meeting Notes & Actions	PDD8901816720			PDD8901816724	AU; H; R; PRE; CON; CU; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2436	Email from Steve Miller to Ilene Sackler re Board Search	PPLPC039001219581			PPLPC039001219582	AU; H; R; PRE; CON; CU; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-2437	Email from Jonathan Sackler re Forbes article about Oxycontin	PDD1781008659	PDD1781008660			PRE; CON; CU; AU; H; R; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2438	Letter to News Director from Howard Udell	PDD1782053801	PDD1782053802			Judicial Estoppel; R; PRE; CON; CU; AU; H; R; PRE; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2439	Presentation by Purdue Speaker Robin Hogen entitled "Victimized Twice: Collateral Damage from the Controversy Surrounding OxyContin"	POK000250501				AU; H; R; PRE; CON; CU	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2440	Drugabuse.gov: "Dramatic Increases in Maternal Opioid Use and Neonatal Abstinence Syndrome" (National Institute on Drug Abuse)					AU; H; R; PRE; CON; CU; Incomplete Document; LF; J-MIL-12; T-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2441	The Journal of the Oklahoma State Medical Association - "Prescription Drug Misuse and Associated Risk Behaviors among Public High School Students in Oklahoma: Data from the 2013 Oklahoma Youth Risk Behavior Survey"				Nguyen 6	AU; H; R; PRE; CON; CU; T-MIL-9	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2442	Email from Jonathan Sackler re OxyContin update 8-2	PDD8801175359	PDD8801175360			AU; H; R; PRE; CON; CU; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2443	Purdue Pharma LP "Hot Spots Project III" Presentation	PPLPC030000233721	PPLPC030000233721			AU; H; R; PRE; CON; CU; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2444	Evolve 2 Excellence Overview Presentation	PPLPC035000198773				AU; H; R; PRE; CON; CU; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2445	Email from Jonathan Sackler re OxyContin Promotional Budget	PDD1701807633	PDD1701807633			AU; H; R; PRE; CON; CU; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2446	Johnson & Johnson - Duragesic Disease Modeling Presentation to the GOC	JAN-MS-00309602				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2447	Teva Advocacy Mapping Presentation	TEVA_OK_00101616				AU; H; LF; V; T-MIL#1; J-MIL-3; R; PRE	

S-2448	Johnson & Johnsons - Partner of Choice in Pharmaceuticals Presentation	JAN-MS-04291847				Inadmissible Character Evidence; R; PRE; CON; CU; AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2449	Protecting Purdue, Providers and Patients - Managing Purdue's Public Exposure	PKY182000431				R; PRE; CON; CU; AU; H; PRE; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2450	CDC: "Vital Signs: Overdoses of Prescription Opioid Pain relievers and Other Drugs among Women, United States, 1999-2010"					AU; H; R; PRE; CON; CU; Incomplete Document; J-MIL-6, J-MIL-12; T-MIL-1; T-MIL-7	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2451	Email from Jonathan Sackler re Oxycodone DEA Quota	PDD1701817989	PDD1701817989			First Amendment; AU; H; R; PRE; CON; CU; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2452	Noramco Organizational Alignment Presentation	JAN-MS-00725219				First Amendment; Nuisance Statute's Safe-harbor; R; PRE; CON; CU; AU; H; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2453	Noramco Letter to Ed Migliarese re supply of oxycodone	PPLP004487917	PPLP004487918			Nuisance Statute's Safe-harbor; AU; H; R; PRE; CON; CU; LF; J-MIL-4; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2454	Email from Richard Sackler re addicts	PPLPC042000003385	PPLPC042000003387			AU; H; R; PRE; CON; CU; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2455	Johnson & Johnson - Duragesic Disease Modeling Workshop 2 Takeaways	JAN-MS-00481547				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2456	Janssen - Demonstrate Industry Leadership in Advocacy for HCPs & Patient Access 2011-12 Advocacy Launch Plan presentation	JAN-MS-00940676				First Amendment; AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2457	Purdue Board Business Development Committee - Project Tango	PPLPC029000601248	PPLPC029000601248			AU; H; R; PRE; CON; CU; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2458						AU; H; R; PRE; CON; CU; Incomplete Document; Not Produced / Cannot Be Located	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2459	Email from Robyn Frenze to Greg Panico re Pain Spokesperson for Investigative Article	JAN-MS-00498861				Nuisance Statute's Safe-harbor; R	12 O.S. 2401, 2402

S-2460	Duragesic: Life, uninterrupted. Summary of Payments made from January 1, 2012 - March 28, 2017 in Response to Ranking Member McCaskill's March 28, 2017 Letter	JAN-MS-00306286				Nuisance Statute's Safe-harbor; Preemption; AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2461	Response to Request 1) Payment listing details (1997 - May 8th, 2012) in response to Senate Finance Committee letter request dated May 8, 2012	JAN-OK-00144167				First Amendment; AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2462	Letter to McCaskill re response to Request 8 enclosing documents	PPLPC046000040438			PPLPC046000040456	Discovery Violations; First Amendment; AU; H; R; PRE; CON; CU; LF; J-MIL-3; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2463	Summary of Payments made from January 1, 2012 - March 28, 2017 in Response to Ranking Member McCaskill's March 28, 2017 Letter	JAN-OK-00144170				First Amendment; AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2464	Vendor invoice/payment info, including Front Group Payments	JAN-OK-00144173				First Amendment; AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2465	Cephalon (Actiq) payments to Front Groups, KOLs, and various companies for various projects.	TEVA_OK_02301917				AU; H; LF; CON; CU; V; R; PRE; T-MIL-1; J-MIL-3	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2466	ACS spreadsheet showing amounts paid	TEVA_OK_01850003				AU; H; LF; CON; CU; V; R; PRE; T-MIL-1; J-MIL-3	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2467	Comprehensive NUCYNTA Trained Speaker List	ACS-CAN-001178			ACS-CAN-001178	AU; H; LF; J-MIL-3; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4; R; PRE	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2468	Clinical Exchange Roundtable Program - DM Training	JAN-MS-00358882				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2469	CME Sponsored by Pricara Insights Into Pain Management 2009	JAN-MS-00662151				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2470	Spreadsheets of contacts made by the medical liasons - counts 2001	JAN-MS-00931773				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2471	states	PPLPC037000012485			PPLPC037000012485	First Amendment; AU; H; R; PRE; CON; CU; LF; J-MIL-3; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-2472	Speaker count by year spreadsheet 2001 - 2005	PPLPC051000038993	PPLPC051000038993			First Amendment; AU; H; R; PRE; CON; CU; LF; J-MIL-3; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2473	Email to Charles Argoff re Content Development Meeting - Consulting Agreement & Important Meeting details	ARGOFF001875	ARGOFF001877			AU; H; R; LF; J-MIL-12; T-MIL-1; PRE	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2474	Speaker Agreement between Cephalon and Charles Argoff	TEVA_OK_13254971				AU; H; LF; T-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2475	Fentora - Fast Team Meeting - Fentora Assessment Strategy Tactics) Presentation	TEVA_OK_00008154				AU; H; LF; T-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2476	Pharmacological Management of Persistent Pain in Older Persons	JAN-MS-01180324				H; R	12 O.S. 2401, 2402; 12 O.S. 2802
S-2477	Faculty for ASPE Educational Programming	NPRO0001TPP00020876				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2478	American Society for Pain Management in Nursing - ASPMIN 24th National Conference Program presentation	ASPMIN00000610	ASPMIN00000693			First Amendment; AU; H; R; LF; J-MIL-3; T-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2479	Speaker Utilization Spreadsheet	TEVA_OK_11605252				AU; H; LF; T-MIL-1; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2480	Community Connects, Pain Management Initiative - Contact Information for Attending Primary Panelists	JAN-MS-00420414				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2481	Janssen Call Notes Documents	JAN-OK-00145252				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2482	Janssen Call Notes Documents	JAN-OK-00145253				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2483	Janssen Call Notes Documents	JAN-OK-00145254				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2484	Janssen Call Notes Documents	JAN-OK-00145255				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-2485	Janssen Call Notes Documents	JAN-OK-00145256				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2486	Janssen Call Notes Documents	JAN-OK-00145257				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2487	Janssen Call Notes Documents	JAN-OK-00145258				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2488	Janssen Call Notes Documents	JAN-OK-00145259				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2489	Janssen Call Notes Documents	JAN-OK-00145260				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2490	Janssen Call Notes Documents	JAN-OK-00145261				Inadmissible Character Evidence; R; PRE; CON; CU; AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2491	Janssen Call Notes Documents	JAN-OK-00145262				Inadmissible Character Evidence; R; PRE; CON; CU; AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2492	Janssen Call Notes Documents	JAN-OK-00145263				Inadmissible Character Evidence; R; PRE; CON; CU; AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2493	Janssen Call Notes Documents	JAN-OK-00000001				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2494	Janssen Call Notes Documents	JAN-OK-00000002				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2495	Janssen Call Notes Documents	JAN-OK-00000003				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2496	Janssen Call Notes Documents	JAN-OK-00000004				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2498	Teva Call Notes Documents	TEVA_OK_00099766				AU; H; R; PRE; CON; CU; Not Produced / Cannot Be Located	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2499	Teva Call Notes Documents	TEVA_OK_00099767				AU; H; R; LF; CU; CON; V; PRE	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2500	Teva Call Notes Documents	TEVA_OK_00099768				AU; H; R; LF; CU; CON; V; PRE	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2501	Teva Call Notes Documents	TEVA_OK_00099769				AU; H; LF; CU; CON; V; R; PRE	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2502	Teva Call Notes Documents	TEVA_OK_00099770				AU; H; LF; CU; CON; V; R; PRE	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-2503	Teva Call Notes Documents	TEVA_OK_00099771				AU; H; LF; CU; CON; V; R; PRE	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2504	Teva Call Notes Documents	TEVA_OK_01060405				AU; H; LF; CU; CON; V; R; PRE	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2505	Teva Call Notes Documents	TEVA_OK_01218835				AU; H; LF; CU; CON; V; T-MIL-1; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2506	Teva Call Notes Documents	TEVA_OK_01218843				AU; H; LF; CU; CON; V; T-MIL-1; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2507	Teva Call Notes Documents	TEVA_OK_02317602				AU; H; LF; CU; CON; V; T-MIL-1; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2508	Purdue Call Notes Document	POK001852070				AU; H; R; PRE; CON; CU; LF; V; T- MIL-1	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2509	Purdue Call Notes Document	POK003477669				AU; H; R; PRE; CON; CU	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2510	Email from Brett Vincent re Duragesic Slide Deck - Med Comm comments attached	JAN-MS-00747490				AU; H; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4; R; PRE	
S-2511	Comment on draft Duragesic KOL Slide Deck (Item 01DR1108) from Vince Brett 11/15/07	JAN-MS-00747497				First Amendment; AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2512	Email - Burt Rose to PCF - Purdue Response to PROP	JAN-MS-00424649				First Amendment; AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2513	Purdue Response to PROP	JAN-MS-00424650				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2514	Email - Pharmacy Duragesic Visual Aid	JAN-MS-00306375				PRE; CON; CU; AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2515	Pharmacy Duragesic Visual Aid	JAN-MS-00306376				PRE; CON; CU; AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2516	Sales Bulletin - Allan Study	JAN-MS-00304333				R; PRE; CON; CU; AU; H; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-2517	Allan Study	JAN-MS-00304334				R; PRE; CON; CU; AU; H; Incomplete Document	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2518	Duragesic Sales Memo - 2002	JAN-MS-00310227				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2519	Duragesic Sales Memo - 2002	JAN-MS-00310230				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2520	Email with Milligan Study attached	JAN-MS-00311758				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2521	Milligan Study	JAN-MS-00311759				First Amendment; H; R	12 O.S. 2401, 2402; 12 O.S. 2802
S-2522	Sales Bulletin - Milligan	JAN-MS-00315416				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2523	Simpson Study	JAN-MS-02580183				H; R	12 O.S. 2401, 2402; 12 O.S. 2802
S-2524	work, interrupted visual aid	JAN-MS-00508566				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2525	email with work interrupted visual aid	JAN-MS-00508553				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2526	Duragesic Training Aid	JAN-MS-00311093				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2527	Duragesic Training Aid	JAN-MS-00311107				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2528	Duragesic Training Aid	JAN-MS-00311121				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2529	Duragesic Training Aid	JAN-MS-00311136				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2530	Email with Duragesic Training Aids	JAN-MS-00311091				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2531	Durogesic Current Claims	JAN-MS-00902751				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2532	2004 AAPM Exhibit Distribution List	JAN-MS-00299665				First Amendment; R; PRE; CON; CU; AU; H; PRE	12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2533	Email - 2004 AAPM Exhibit Distribution List	JAN-MS-00299663				First Amendment; R; PRE; CON; CU; H; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2802
S-2534	Duragesic Selling Tools	JAN-MS-00789160				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2535	Email - Duragesic Selling Tools	JAN-MS-00789159				R; PRE; CON; CU; AU; H; PRE	12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-2536	Presentation - 3rd cycle DM RBD Meeting	JAN-MS-00789162				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2537	Presentation - Sales Force - 2002	JAN-MS-00790267				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2538	2002 Hospital Sales Force Presentation	JAN-MS-00784263				First Amendment; AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2539	Duragesic Green Sales Force Meeting - Chicago	JAN-MS-00784265				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2540	DM Cycle Prep Meeting - December, 2003	JAN-MS-03070408				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2541	JJ Advocacy Presentation - Alliance Management	JAN-MS-00399862				First Amendment; AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2542	JJ Strategic Plan Support Research	JAN-MS-00306126				R; PRE; CON; CU; AU; H; PRE	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2543	2001 Email with Joranson, Simpson, etc.	JAN-MS-00304252				INC; CON; H	
S-2544	Key Reprints Presentation with Joranson, Simpson, etc.	JAN-MS-00304253				CON; AU; H; CU; SUM	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2545	Pain Specialist Backgrounder	JAN-MS-02757640				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2546	JJ 2001 Business Plan	JAN-MS-00618253				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2547	Nucynta Speaker Bureau Leveling	JAN-MS-01082851				First Amendment; AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2548	Nucynta Training Doc	JAN-MS-00106322				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2549	Nucynta Message Convergence Exploration	JAN-MS-00074291				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2550	JJ Prescription Counts - Q1 2015	JAN-MS-02734175				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2551	NEP Campaign Total April 2007 - March 2008	JAN-OK-00138659				AU; H; R; PRE; CON; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2552	NEP Campaign Total April 2007 - March 2008	JAN-OK-00138660				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2553	NEP Campaign Total April 2007 - March 2008	JAN-OK-00138661				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-2554	NEP Campaign Total April 2007 - March 2008	JAN-OK-00138662			AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2555	NEP Campaign Total April 2007 - March 2008	JAN-OK-00138663			AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2556	NEP Campaign Total April 2007 - March 2008	JAN-OK-00138664			AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2557	NEP Campaign Total April 2007 - March 2008	JAN-OK-00138665			AU; H; R; PRE; CON; CU	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2558	NEP Campaign Total April 2007 - March 2008	JAN-OK-00138666			AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2559	NEP Campaign Total April 2007 - March 2008	JAN-OK-00138667			AU; H; R; PRE; CON; CU	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2560	NEP Campaign Total April 2007 - March 2008	JAN-OK-00138668			AU; H; R; PRE; CON; CU	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2561	NEP Campaign Total April 2007 - March 2008	JAN-OK-00138669			AU; H; R; PRE; CON; CU	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2562	NEP Campaign Total April 2007 - March 2008	JAN-OK-00138670			AU; H; R; PRE; CON; CU	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2563	NEP Campaign Total April 2007 - March 2008	JAN-OK-00138671			AU; H; R; PRE; CON; CU	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2564	PriCara 2H08 Target List	JAN-OK-00138672			AU; H; R; PRE; CON; CU	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2565	PriCara 2H08 Target List	JAN-OK-00138673			AU; H; R; PRE; CON; CU	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2566	PriCara 2H08 Target List	JAN-OK-00138674			AU; H; R; PRE; CON; CU	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2567	PriCara 2H08 Target List	JAN-OK-00138675			AU; H; R; PRE; CON; CU	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2568	PriCara 2H08 Target List	JAN-OK-00138676			AU; H; R; PRE; CON; CU	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-2569	PriCara 2H08 Target List	JAN-OK-00138677				AU; H; R; PRE; CON; CU	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2570	PriCara 2H08 Target List	JAN-OK-00138678				AU; H; R; PRE; CON; CU	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2571	NEO Pathways Campaign 20-Jun-08	JAN-OK-00138679				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2572	Oklahoma specific sales representative call notes.	JAN-OK-00138701				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2573	PAIN IC Plan Materials and territory Goal Summary Report	JAN-MS-02911122				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2574	PAIN IC Plan Materials and territory Goal Summary Report	JAN-MS-02911120				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2575	PAIN IC Plan Materials and territory Goal Summary Report	JAN-MS-02911121				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2576	PAIN IC Plan Materials and territory Goal Summary Report	JAN-MS-02911123				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2577	Nucynta Regional Data - Goals	JAN-MS-02948029				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2578	Duragesic Fact Sheet	JAN-MS-00246752				AU; H	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2579	Duragesic Grow and Defend Email	JAN-MS-00369997				AU; H; R	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2580	Grow and Defend Excel Sheet	JAN-MS-00369998				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2581	Duragesic Making Connections Program ROI Analysis	JAN-MS-00314937				AU; H	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2582	Balanced Scorecard Worksheet	JAN-MS-00246970				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2583	Eaton Assoc. Presentation on ADF	JAN-MS-00423554				R; PRE; CON; CU; AU; H; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2584	DAW Presentation - 2004	JAN-MS-00479441				R; PRE; CON; CU; AU; H; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2585	Joe Pecora Dec - March 06	JAN-MS-00588611				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-2586	Joe Pecora Dec - March 06	JAN-MS-02018188				R; PRE; CON; CU; AU; H; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2587	2011 Prescriber Data	JAN-OK-00134543				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2588	Plano LAO Market Data	JAN-OK-00137484				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2589	Institution Prescription Data	JAN-OK-00137485				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2590	Institution Prescription Data	JAN-OK-00137486				R; CON	
S-2591	Institution Prescription Data	JAN-OK-00137487				R; CON	
S-2592	Institution Prescription Data	JAN-OK-00137848				AU; H; R; PRE; CON; CU	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2593	PriCara 2H07 Target List	JAN-OK-00138643				AU; H; R; PRE; CON; CU	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2594	Nucynta Promotional Activity & Launch Performance follow up 2010	JAN-MS-00808894				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2595	2004 Green Force KOL Listing w/ OK Doctors - email cover	JAN-MS-00303911				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2596	2004 Green Force KOL Listing w/ OK Doctors	JAN-MS-00303912				R; PRE; CON; CU; AU; H; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2597	Email - Top Actiq Coupon Users wTRxs - Coupon & TRx Totals for June 2003 to May 2004	TEVA_OK_00944528				AU; H; LF; CU; CON; V; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2598	Top Actiq Coupon Users wTRxs - Coupon & TRx Totals for June 2003 to May 2004	TEVA_OK_00944529				AU; H; LF; T-MIL#1; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2599	Actiq TRX Counts	TEVA_OK_04960630				AU; H; LF; T-MIL#1; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2600	Actiq TRX Counts	TEVA_OK_04961022				AU; H; LF; CU; CON; V; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2601	Actiq TRX Counts	TEVA_OK_04961288				AU; H; LF; CU; CON; V; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-2602	Actiq TRX Counts	TEVA_OK_04961493				AU; H; LF; CU; CON; V; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2603	Actiq TRX Counts	TEVA_OK_04961622				AU; H; LF; CU; CON; V; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2604	Actiq TRX Counts	TEVA_OK_04961768				AU; H; LF; CU; CON; V; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2605	Actiq TRX Counts	TEVA_OK_04962568				AU; H; LF; CU; CON; V; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2606	Actiq TRX Counts	TEVA_OK_04962735				AU; H; LF; CU; CON; V; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2607	Actiq TRX Counts	TEVA_OK_04963175				AU; H; LF; CU; CON; V; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2608	Actiq TRX Counts	TEVA_OK_04963268				AU; H; LF; CU; CON; V; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2609	Actiq TRX Counts	TEVA_OK_04965381				AU; H; LF; CU; CON; V; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2610	Actiq TRX Counts	TEVA_OK_04967989				AU; H; LF; CU; CON; V; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2611	Actiq TRX Counts	TEVA_OK_04970448				AU; H; LF; CU; CON; V; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2612	Actiq TRX Counts	TEVA_OK_04972172				AU; H; LF; CU; CON; V; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2613	Actiq TRX Counts	TEVA_OK_04974002				AU; H; LF; CU; CON; V; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2614	Actiq TRX Counts	TEVA_OK_04975863				AU; H; LF; CU; CON; V; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-2615	Actiq TRX Counts	TEVA_OK_04978390				AU; H; LF; CU; CON; V; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2616	Actiq TRX Counts	TEVA_OK_04980304				AU; H; LF; CU; CON; V; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2617	Actiq TRX Counts	TEVA_OK_04983151				AU; H; LF; CU; CON; V; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2618	Actiq TRX Counts	TEVA_OK_04985425				AU; H; LF; CU; CON; V; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2619	Actiq TRX Counts	TEVA_OK_04987714				AU; H; LF; CU; CON; V; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2620	Actiq Performance Script Coupons	TEVA_OK_04981142				AU; H; LF; CU; CON; V; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2621	Actiq Performance Script Coupons	TEVA_OK_04981143				AU; H; LF; CU; CON; V; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2622	Actiq Performance Script Coupons	TEVA_OK_04981144				AU; H; LF; CU; CON; V; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2623	Actiq Performance Script Coupons	TEVA_OK_04981145				AU; H; LF; CU; CON; V; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2624	Actiq Performance Script Coupons	TEVA_OK_04981146				AU; H; LF; CU; CON; V; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2625	Actiq Performance Script Coupons	TEVA_OK_04981147				AU; H; LF; CU; CON; V; R; PRE; T-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2626	Actiq Performance Script Coupons	TEVA_OK_04981148				AU; H; LF; CU; CON; V; R; PRE; T-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2627	Actiq Performance Script Coupons	TEVA_OK_04964618				AU; H; LF; CU; CON; V; R; PRE; T-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-2628	Actiq Performance Script Coupons	TEVA_OK_04964821				AU; H; LF; CU; CON; V; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2629	Actiq Performance Script Coupons	TEVA_OK_04964849				AU; H; LF; CU; CON; V; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2630	Actiq Performance Script Coupons	TEVA_OK_04967623				AU; H; LF; CU; CON; V; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2631	Actiq Performance Script Coupons	TEVA_OK_04971314				AU; H; LF; CU; CON; V; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2632	Actiq Performance Script Coupons	TEVA_OK_04972492				AU; H; LF; CU; CON; V; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2633	Actiq Performance Script Coupons	TEVA_OK_04973038				AU; H; LF; CU; CON; V; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2634	Actiq Performance Script Coupons	TEVA_OK_04974963				AU; H; LF; CU; CON; V; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2635	Actiq Performance Script Coupons	TEVA_OK_04974964				AU; H; LF; CU; CON; V; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2636	Actiq Performance Script Coupons	TEVA_OK_04974965				AU; H; LF; CU; CON; V; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2637	Actiq Performance Script Coupons	TEVA_OK_04974966				AU; H; LF; CU; CON; V; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2638	Actiq Performance Script Coupons	TEVA_OK_04974967				AU; H; LF; CU; CON; V; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2639	Actiq Performance Script Coupons	TEVA_OK_04976694				AU; H; LF; CU; CON; V; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2640	Actiq Performance Script Coupons	TEVA_OK_04976695				AU; H; LF; CU; CON; V; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-2641	Actiq Performance Script Coupons	TEVA_OK_04976696				AU; H; LF; CU; CON; V; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2642	Actiq Performance Script Coupons	TEVA_OK_04976853				AU; H; LF; CU; CON; V; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2643	Actiq Performance Script Coupons	TEVA_OK_04976854				AU; H; LF; CU; CON; V; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2644	Actiq Performance Script Coupons	TEVA_OK_04976855				AU; H; LF; CU; CON; V; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2645	Actiq Performance Script Coupons	TEVA_OK_04976856				AU; H; LF; CU; CON; V; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2646	Actiq Performance Script Coupons	TEVA_OK_04978739				AU; H; LF; CU; CON; V; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2647	Actiq Performance Script Coupons	TEVA_OK_04978740				AU; H; LF; CU; CON; V; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2648	Actiq Performance Script Coupons	TEVA_OK_04978741				AU; H; LF; CU; CON; V; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2649	Actiq Performance Script Coupons	TEVA_OK_04978742				AU; H; LF; CU; CON; V; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2650	Actiq Performance Script Coupons	TEVA_OK_04979415				AU; H; LF; CU; CON; V; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2651	Actiq Performance Script Coupons	TEVA_OK_04979416				AU; H; LF; CU; CON; V; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2652	Actiq Performance Script Coupons	TEVA_OK_04979417				AU; H; LF; CU; CON; V; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2653	Actiq Performance Script Coupons	TEVA_OK_04981142				AU; H; LF; CU; CON; V; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-2654	Actiq Performance Script Coupons	TEVA_OK_04981143				AU; H; LF; CU; CON; V; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2655	Actiq Performance Script Coupons	TEVA_OK_04981144				AU; H; LF; CU; CON; V; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2656	Actiq Performance Script Coupons	TEVA_OK_04981145				AU; H; LF; CU; CON; V; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2657	Actiq Performance Script Coupons	TEVA_OK_04981773				AU; H; LF; CU; CON; V; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2658	Actiq Performance Script Coupons	TEVA_OK_04981774				AU; H; LF; CU; CON; V; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2659	Actiq Performance Script Coupons	TEVA_OK_04981775				AU; H; LF; CU; CON; V; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2660	Actiq Performance Script Coupons	TEVA_OK_04983966				AU; H; LF; CU; CON; V; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2661	Actiq Performance Script Coupons	TEVA_OK_04983967				AU; H; LF; CU; CON; V; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2662	Actiq Performance Script Coupons	TEVA_OK_04983968				AU; H; LF; CU; CON; V; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2663	Actiq Performance Script Coupons	TEVA_OK_04988486				AU; H; LF; CU; CON; V; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2664	Actiq Performance Script Coupons	TEVA_OK_04988487				AU; H; LF; CU; CON; V; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2665	Actiq Performance Script Coupons	TEVA_OK_04988488				AU; H; LF; CU; CON; V; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2666	Actiq Performance Script Coupons	TEVA_OK_04991870				AU; H; LF; CU; CON; V; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-2667	Actiq Performance Script Coupons	TEVA_OK_04991871				AU; H; LF; CU; CON; V; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2668	Actiq Performance Script Coupons	TEVA_OK_04991953				AU; H; LF; CU; CON; V; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2669	Actiq Performance Script Coupons	TEVA_OK_04991954				AU; H; LF; CU; CON; V; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2670	Actiq Performance Script Coupons	TEVA_OK_04993122				AU; H; LF; CU; CON; V; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2671	Actiq Performance Script Coupons	TEVA_OK_04994241				AU; H; LF; CU; CON; V; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2672	Actiq Performance Script Coupons	TEVA_OK_04994242				AU; H; LF; CU; CON; V; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2673	Actiq Performance Script Coupons	TEVA_OK_04994328				AU; H; LF; CU; CON; V; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2674	Actiq Performance Script Coupons	TEVA_OK_04994329				AU; H; LF; CU; CON; V; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2675	Actiq Performance Script Coupons	TEVA_OK_04996490				AU; H; LF; CU; CON; V; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2676	Email re: Segmentation Reports	TEVA_OK_11767189				AU; H; LF; CU; CON; V; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2677	Doc DEA Numbers	TEVA_OK_05024051				AU; H; LF; T-MIL#1; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2678	Fentora Patient Voucher Utilization - 2011	TEVA_OK_00572009				AU; H; LF; T-MIL#1; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2679	Fentora 2011 - Voucher Utilization	TEVA_OK_00572010				AU; H; LF; T-MIL#1; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-2680	Email - Growth / Loss Reports	TEVA_OK_01067873				AU; H; LF; CU; CON; V; T-MIL#1; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2681	Fentora Loss / Gain Report	TEVA_OK_00944542				AU; H; LF; T-MIL-1; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2682	Fentora Loss / Gain Report	TEVA_OK_01060975				AU; H; LF; CU; CON; V; T-MIL-1; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2683	Fentora Loss / Gain Report	TEVA_OK_01067876				AU; H; LF; CU; CON; V; T-MIL-1; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2684	Fentora Loss / Gain Report	TEVA_OK_01067879				AU; H; LF; CU; CON; V; T-MIL-1; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2685	Fentora Loss / Gain Report - 2008	TEVA_OK_02254549				AU; H; LF; CU; CON; V; T-MIL-1; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2686	Fentora Loss / Gain Report - 2008	TEVA_OK_03037328				AU; H; LF; CU; CON; V; T-MIL-1; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2687	Fentora Loss / Gain Report - 2008	TEVA_OK_03037337				AU; H; LF; CU; CON; V; T-MIL-1; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2688	2008 Fentora Script Data	TEVA_OK_01222438				AU; H; LF; CU; CON; V; T-MIL-1; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2689	2008 Fentora Script Data	TEVA_OK_01222439				AU; H; LF; CU; V; CON; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2690	2008 Fentora Script Data	TEVA_OK_01222440				AU; H; LF; CU; V; CON; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2691	2008 Fentora Script Data	TEVA_OK_01222441				AU; H; LF; CU; V; CON; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2692	2008 Fentora Script Data	TEVA_OK_01222442				AU; H; LF; CU; V; CON; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-2693	2008 Fentora Script Data	TEVA_OK_01222443				AU; H; LF; CU; V; CON; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2694	2008 Fentora Script Data	TEVA_OK_01222444				AU; H; LF; CU; V; CON; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2695	2008 Fentora Script Data	TEVA_OK_01222445				AU; H; LF; CU; V; CON; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2696	2008 Fentora Script Data	TEVA_OK_01222446				AU; H; LF; CU; V; CON; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2697	2008 Fentora Script Data	TEVA_OK_01222447				AU; H; LF; CU; V; CON; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2698	2008 Fentora Script Data	TEVA_OK_01222448				AU; H; LF; CU; V; CON; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2699	Fentora Script Data	TEVA_OK_01222449				AU; H; LF; CU; V; CON; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2700	Fentora Script Data	TEVA_OK_01222450				AU; H; LF; CU; V; CON; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2701	Fentora Script Data	TEVA_OK_01222451				AU; H; LF; CU; V; CON; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2702	Fentora Script Data	TEVA_OK_01222452				AU; H; LF; CU; V; CON; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2703	Fentora Script Data	TEVA_OK_01222453				AU; H; LF; CU; V; CON; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2704	Fentora Script Data	TEVA_OK_01222454				AU; H; LF; CU; V; CON; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2705	Fentora Script Data	TEVA_OK_01222455				AU; H; LF; CU; V; CON; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-2706	Fentora Script Data	TEVA_OK_01222456				AU; H; LF; CU; V; CON; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2707	Fentora Script Data	TEVA_OK_01222457				AU; H; LF; CU; V; CON; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2708	Fentora Script Data	TEVA_OK_01222458				AU; H; LF; CU; V; CON; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2709	Fentora Script Data	TEVA_OK_01222459				AU; H; LF; CU; V; CON; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2710	Fentora Script Data	TEVA_OK_01222460				AU; H; LF; CU; V; CON; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2711	Fentora Script Data	TEVA_OK_01222461				AU; H; LF; CU; V; CON; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2712	Fentora Script Data	TEVA_OK_01222462				AU; H; LF; CU; V; CON; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2713	Fentora Script Data	TEVA_OK_01222463				AU; H; LF; CU; V; CON; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2714	Fentora Script Data	TEVA_OK_01222464				AU; H; LF; CU; V; CON; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2715	Fentora Script Data	TEVA_OK_01222465				AU; H; LF; CU; V; CON; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2716	Fentora Script Data	TEVA_OK_01222466				AU; H; LF; CU; V; CON; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2717	Fentora Script Data	TEVA_OK_01222467				AU; H; LF; CU; V; CON; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2718	Fentora Script Data	TEVA_OK_01222468				AU; H; LF; CU; V; CON; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-2719	Fentora Script Data	TEVA_OK_01222469				AU; H; LF; CU; V; CON; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2720	Fentora Script Data	TEVA_OK_01222470				AU; H; LF; CU; V; CON; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2721	Fentora Script Data	TEVA_OK_01222471				AU; H; LF; CU; V; CON; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2722	Fentora Script Data	TEVA_OK_01222472				AU; H; LF; CU; V; CON; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2723	Fentora Script Data	TEVA_OK_01222473				AU; H; LF; CU; V; CON; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2724	Fentora Script Data	TEVA_OK_01222474				AU; H; LF; CU; V; CON; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2725	Fentora Script Data	TEVA_OK_01222475				AU; H; LF; CU; V; CON; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2726	Fentora Script Data	TEVA_OK_01222476				AU; H; LF; CU; V; CON; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2727	Fentora Script Data	TEVA_OK_01222477				AU; H; LF; CU; V; CON; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2728	Fentora Script Data	TEVA_OK_01222478				AU; H; LF; CU; V; CON; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2729	Fentora Script Data	TEVA_OK_01222479				AU; H; LF; CU; V; CON; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2730	Fentora Script Data	TEVA_OK_01222480				AU; H; LF; CU; V; CON; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2731	All one doc with attachments with Gain Loss Reports	TEVA_OK_02254546				AU; H; LF; CU; V; CON; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-2732	All one doc with attachments with Gain Loss Reports	TEVA_OK_02254547			AU; H; LF; CU; V; CON; T-MIL-1; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2733	All one doc with attachments with Gain Loss Reports	TEVA_OK_02254548			AU; H; LF; CU; V; CON; T-MIL-1; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2734	All one doc with attachments with Gain Loss Reports	TEVA_OK_02254549			AU; H; LF; CU; V; CON; T-MIL-1; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2735	All one doc with attachments with Gain Loss Reports	TEVA_OK_02254550			AU; H; LF; CU; V; CON; T-MIL-1; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2736	All one doc with attachments with Gain Loss Reports	TEVA_OK_02254551			AU; H; LF; CU; V; CON; T-MIL-1; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2737	All one doc with attachments with Gain Loss Reports	TEVA_OK_02254552			AU; H; LF; CU; V; CON; T-MIL-1; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2738	All one doc with attachments with Gain Loss Reports	TEVA_OK_02254553			AU; H; LF; CU; V; CON; T-MIL-1; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2739	All one doc with attachments with Gain Loss Reports	TEVA_OK_02254554			AU; H; LF; CU; V; CON; T-MIL-1; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2740	All one doc with attachments with Gain Loss Reports	TEVA_OK_02254555			AU; H; LF; CU; V; CON; T-MIL-1; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2741	All one doc with attachments with Gain Loss Reports	TEVA_OK_02254556			AU; H; LF; CU; V; CON; T-MIL-1; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2742	All one doc with attachments with Gain Loss Reports	TEVA_OK_02254557			AU; H; LF; CU; V; CON; T-MIL-1; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2743	All one doc with attachments with Gain Loss Reports	TEVA_OK_02254558			AU; H; LF; CU; V; CON; T-MIL-1; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2744	All one doc with attachments with Gain Loss Reports	TEVA_OK_02254559			AU; H; LF; CU; V; CON; T-MIL-1; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-2745	All one doc with attachments with Gain Loss Reports	TEVA_OK_02254560			AU; H; LF; CU; V; CON; T-MIL-1; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2746	All one doc with attachments with Gain Loss Reports	TEVA_OK_02254561			AU; H; LF; CU; V; CON; T-MIL-1; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2747	All one doc with attachments with Gain Loss Reports	TEVA_OK_02254562			AU; H; LF; CU; V; CON; T-MIL-1; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2748	All one doc with attachments with Gain Loss Reports	TEVA_OK_02254563			AU; H; LF; CU; V; CON; T-MIL-1; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2749	All one doc with attachments with Gain Loss Reports	TEVA_OK_02254564			AU; H; LF; CU; V; CON; T-MIL-1; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2750	Presentation - Targeting	TEVA_OK_00041510			AU; H; LF; CU; V; CON; T-MIL-1; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2751	Mission Impossible Actiq	TEVA_OK_07415268			AU; H; LF; T-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2752	Mission Impossible Actiq	TEVA_OK_07787184			AU; H; LF; T-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2753	Manager Pilot Training	TEVA_OK_01514618			AU; H; LF; T-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2754	PDF Excel chart of Actiq call data	TEVA_OK_07435454			AU; H; LF; T-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2755	PDF Excel chart of Actiq call data	TEVA_OK_07493525			AU; H; LF; CU; V; CON; R; PRE; T-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2756	PDF Excel chart of Actiq call data	TEVA_OK_07494423			AU; H; LF; CU; V; CON; R; PRE; T-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2757	Excel chart of Actiq call data	TEVA_OK_10129941			AU; H; LF; CU; V; CON; R; PRE; T-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-2758	Email for TEVA_OK_10129941	TEVA_OK_10129940				AU; H; LF; CU; V; CON; R; PRE; T-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2759	Excel chart of Actiq call data	TEVA_OK_01517048				AU; H; LF; V; CON; R; PRE; T-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2760	Email for TEVA_OK_01517048	TEVA_OK_01517047				AU; H; LF; CU; V; CON; R; PRE; T-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2761	CL: SS showing honoraria paid to speakers in OK in 2006-2013	TEVA_OK_00099767				AU; H; LF; V; CON; R; PRE; T-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2762	Email - Promotional Sensitivity Analysis for Speakers Bureaus	TEVA_OK_02900318				AU; H; LF; CU; V; CON; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2763	Promotional Sensitivity Analysis for Speakers Bureaus	TEVA_OK_02900319				AU; H; LF; T-MIL-1; V; CON; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2764	Kent Smalley Speaker Agreement - 2005	TEVA_OK_13248571				AU; H; LF; T-MIL-1; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2765	Kent Smalley Speaker Agreement - 2004	TEVA_OK_13247261				AU; H; LF; T-MIL-1; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2766	Region 65 Segmentation Report - 5/3/05	TEVA_OK_11767189				AU; H; LF; T-MIL-1; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2767	Region 65 Segmentation Report	TEVA_OK_11767190				AU; H; LF; T-MIL-1; V; CON; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2768	Region 65 Segmentation Report	TEVA_OK_11767191				AU; H; LF; CON; CU; V; T-MIL-1; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2769	Region 65 Segmentation Report	TEVA_OK_11767192				AU; H; LF; CON; CU; V; T-MIL-1; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2770	Region 65 Segmentation Report	TEVA_OK_11767193				AU; H; LF; CON; CU; V; T-MIL-1; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-2771	Region 65 Segmentation Report	TEVA_OK_11767194			AU; H; LF; CON; CU; V; T-MIL-1; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2772	Region 65 Segmentation Report	TEVA_OK_11767195			AU; H; LF; CON; CU; V; T-MIL-1; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2773	Region 65 Segmentation Report	TEVA_OK_11767193			AU; H; LF; CON; CU; V; T-MIL-1; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2774	Region 65 Segmentation Report	TEVA_OK_11767173			AU; H; LF; CON; CU; V; T-MIL-1; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2775	Region 65 Segmentation Report	TEVA_OK_11767174			AU; H; LF; V; T-MIL-1; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2776	Region 65 Segmentation Report	TEVA_OK_11767175			AU; H; LF; CON; CU; V; T-MIL-1; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2777	Region 65 Segmentation Report	TEVA_OK_11767176			AU; H; LF; CON; CU; V; T-MIL-1; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2778	Region 65 Segmentation Report	TEVA_OK_11767177			AU; H; LF; CON; CU; V; T-MIL-1; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2779	Region 65 Segmentation Report	TEVA_OK_11767178			AU; H; LF; CON; CU; V; T-MIL-1; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2780	Region 65 Segmentation Report	TEVA_OK_11767179			AU; H; LF; CON; CU; V; T-MIL-1; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2781	Region 65 Segmentation Report	TEVA_OK_11767180			AU; H; LF; CON; CU; V; T-MIL-1; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2782	Manager Pilot Training	TEVA_OK_11767025			AU; H; LF; T-MIL-1; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2783	Manager Pilot Training	TEVA_OK_11767026			AU; H; LF; T-MIL-1; R; PRE; V	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-2784	Manager Pilot Training	TEVA_OK_11767027				AU; H; LF; CON; CU; V; T-MIL-1; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2785	Speaker Cleanup - 6/22/05	TEVA_OK_11626513				AU; H; LF; CON; CU; V; T-MIL-1; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2786	2002 Cephalon PR Activities Presentation	TEVA_OK_05305994				AU; H; LF; V; Subject of T-MIL#1	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2787	Cephalon KOL Presentation	TEVA_OK_03063698				AU; H; LF; V; T-MIL-1; T-MIL-10, R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2788	Teva Patient Kit	TEVA_OK_00010858				AU; H; LF; V; T-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2789	"Baltimore Notes" (TS, 1908), box 43, USIOC, with minor spelling corrections and paragraph breaks.					AU; H; R; LF; T-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2790	"Committee on Drug Addiction and Narcotics Meetings: 5th: Minutes: 5/11/49" (TS, 1949), pp. 76-78, Committees on Drug Addiction, Drug Addition (Advisory), and Drug Addition and Narcotics, 1928- 1965, Archives of the National Academy of Sciences, Washington, D.C., with acknowledgment to Professor David Herzberg for calling this document to my attention.					AU; H; R; LF; INC; IC; V; PRE; J-MIL-12; T-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2791	"Drug Amidone an Opiate" (TS, 1947), subsequently printed and dated in Statutes at Large , vol. 61, part 2 (Washington, D.C.: Government Printing Office, 1948), 1075; "General Circular No. 181" (TS, 1947); and I.H. Small to Will S. Wood, September 9, 1947, and Wood to Small, September 15, 1947, all Amidone file.					AU; H; R; LF; IC; V; PRE; J-MIL-12; T-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-2792	"Heroin Hydrochloride," JAMA 47 (1906): 1303.					AU; H; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2793	"Portland, Maine, Notes" (TS, 1908), no pp. ("unscrupulous")					AU; H; R; LF; PRE; J-MIL-12; T-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2794	"Professor Henry P. Hynson," Drug Trade Weekly 4 (April 23, 1921), 15					H; R; AU; LF; IC; V; PRE; J-MIL-12; T-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2802
S-2795	"Questionnaire [sic] re Drug Habit," box 6, and Kolb to Remig, November 14, 1927, box 4, both Lawrence Kolb Papers, History of Medicine Division, National Library of Medicine, Bethesda, Maryland.					AU; H; R; LF; IC; PRE; T-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2796	"The Dope Doctor and Other City Cousins of the Moonshiner," Survey 44 (1920), 18 (routinists).					AU; H; R; Kolb to Remig; AU; INC; IC; LF; PRE; J-MIL-12; T-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2797	"The Opium Habit's Power," New York Times, December 30, 1877, p. 8					H; R; AU; LF; IC; PRE; J-MIL-12; T-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2802
S-2798	"Tolerance and Addiction Liability of 4, 4-Diphenyl-6-Dimethylamino-Hepato-3" (TS, 1947), "Amidone Investigation," file 0480-203A [hereafter Amidone file], Records of the Drug Enforcement Administration, RG 170, National Archives II, College Park, Maryland.					AU; H; R; LF; IC; PRE; J-MIL-12; T-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2799	"We Want to Know," Pharmaceutical Era 29 (1903): 44 ("greedy")					AU; H; R; PR/AU; INC; IC; LF; CON; V; PRE; J-MIL-12; T-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2800	21 CFR Ch. II (April 1, 1996 edition) §§ 1301.73, 1301.74					AU; H; R; LF; IC; V; PRE; J-MIL-12; T-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-2801	Acker, Creating the American Junkie ; Richard J. Bonnie and Charles H. Whitebread II, The Marijuana Conviction: A History of Marijuana Prohibition in the United States (New York: Lindesmith Center, 1999); Courtwright, Dark Paradise ; Courtwright, Joseph, and Des Jarlais, Addicts Who Survived						AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2802	Edward M. Brecher and the Editors of Consumer Reports , Licit and Illicit Drugs (Boston: Little, Brown, 1972)						AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2803	Brian T. Yeh, "The Controlled Substances Act: Regulatory Requirements," Congressional Research Service, December 13, 2012, p. 4, https://fas.org/sgp/crs/misc/RL34635.pdf ("closed")						AU; H; R; PRE; PO; SUM; CON; PR/AU; LF; T-MIL-1; J-MIL-1.	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2804	Burroughs to Allen Ginsberg, April 20, 1955, The Letters of William S. Burroughs, 1945-1959 , ed. Oliver Harris (New York: Viking, 1993), 273						AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2805	Carl Scheffel, "The Etiology of Fifty Cases of Drug Addictions," Medical Record 94 (1918): 853-854						AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2806	Caroline Jean Acker, "From All-Purpose Anodyne to Marker of Deviance: Physicians' Attitudes towards Opiates in the US from 1890 to 1940," in Drugs and Narcotics in History , ed. Roy Porter and Mikuláš Teich (Cambridge: Cambridge University Press, 1995), 128						AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-2807	Caroline Jean Acker, Creating the American Junkie: Addiction Research in the Classic Era of Narcotic Control (Baltimore: Johns Hopkins University Press, 2002), 1-12					AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2808	CDAN meeting minutes of April 15, 1947 (Anslinger quotations) and April 22, 1947; Lewis H. Weed to Secretary of the Treasury John W. Snyder, April 24, 1947 ("spread"), all Amidone file					AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2809	Charles A. West to Hamilton Wright, August 14, 1908, vol. 3, Massachusetts to New Mexico correspondence, USIOC					AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2810	Charles E. Sceleth and Sydney Kuh, "Drug Addiction," JAMA 82 (1924): 679					H; R; PRE; AU; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2802
S-2811	Charles E. Terry and Mildred Pellens, The Opium Problem, reprint ed. (Montclair, N.J.: Patterson Smith, 1970)					AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2812	Committee on Federal Regulation of Methadone Treatment, Division of Biobehavioral Sciences and Mental Disorders, Institute of Medicine, Federal Regulation of Methadone Treatment, ed. Richard A. Rettig and Adam Yarmolinsky (Washington, D.C.: National Academy Press, 1995), chaps. 4-5					AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2813	David F. Musto, The American Disease: Origins of Narcotic Control (New Haven and New York: Yale and Oxford University Presses, three editions [1973, 1987, 1999]);					AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-2814	David Herzberg, "Big Pharma's Real Nemesis? Putting the FBN back into Pharmaceutical History," paper for the American Association of the History of Medicine annual meeting, Chicago, May 10, 2014						AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2815	David Herzberg, "Entitled to Addiction? Pharmaceuticals, Race, and America's First Drug War," Bulletin of the History of Medicine 91 (2017): 586-623						AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2816	David Herzberg, Happy Pills in America: From Milton to Prozac (Baltimore: Johns Hopkins University Press, 2009);						AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2817	David T. Courtwright, "The Controlled Substances Act: How a 'Big Tent' Reform Became a Punitive Drug Law," Drug and Alcohol Dependence 76 (2004): 9-15						AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2818	David T. Courtwright, "The Roads to H: The Emergence of an American Heroin Complex, 1898-1956," in One Hundred Years of Heroin, ed. David F. Musto et al. (Auburn House: Westport, Conn., 2002), 4- 5						AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2819	David T. Courtwright, Dark Paradise: A History of Opiate Addiction in America, rev. ed. (Cambridge, Mass.: Harvard University Press, 2001), chap. 2						AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2820	David T. Courtwright, Herman Joseph, and Don Des Jarlais, Addicts Who Survived: An Oral History of Narcotic Use in America before 1965, rev. ed. (Knoxville: University of Tennessee Press, 2012), 174- 175 (Dilaudid prescription)						AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2821	Dorland's Illustrated Medical Dictionary, 25th ed. (Philadelphia: W.B. Saunders, 1974), 1092						AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-2822	E. W. Shipman, "The Promiscuous Use of Opium in Vermont," Transactions of the Vermont Medical Society, no vol. (1890), 74-75					AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2823	Federal Drug Control: The Evolution of Policy and Practice, ed. Jonathon Erlen and Joseph F. Spillane (New York: Pharmaceutical Products Press, 2004)					AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2824	Fred. [sic] Herman Hubbard, The Opium Habit and Alcoholism (New York: A.S. Barnes & Co., 1881), 17					AU; H; R; PRE; CON; CU; LF; PR/AU; INC; INA; V; PO	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2825	George E. Pettey, "The Heroin Habit Another Curse," Alabama Medical Journal 15 (1903): 174-180, capitalization thus					AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2826	Henry T. Byford et al., An American Text-Book of Gynecology, second rev. ed. (Philadelphia: W.B. Saunders, 1898), 105					AU; H; R; PRE; CON; CU; LF; PR/AU; INC; INA; V; PO	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2827	Herdman comment on C.B. Burr, "Concerning Morphine Addiction and Its Treatment," JAMA 39 (1902): 1592					AU; H; R; PRE; CON; CU; LF; PR/AU; INC; INA; V; PO	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2828	Hubbard, Opium Habit, 162. H. H. Kane, Drugs that Enslave: The Opium, Morphine, Chloral and Hashisch Habits (Philadelphia: Presley Blakiston, 1881), chaps. 2, 7.					AU; H; R; PRE; CON; CU; LF; PR/AU; INC; INA; V; PO	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2829	Hugo Krueger et al., The Pharmacology of the Opium Alkaloids, part 2, supplement no. 165 to the Public Health Reports (Washington, D.C.: Government Printing Office, 1943), 1089-93					AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-2830	J. G. Sewall, "Opium-Eating and Hypodermic Injection," Medical Record 5 (1870): 137; H. Gibbons, "Lethaemia: The Result of the Hypodermic Injection of Morphia," Pacific Medical Journal 12 (1870): 481-495; Clifford Albutt, "On the Abuse of Hypodermic Injections of Morphia," Practitioner 5 (1870): 327-331					AU; H; R; PRE; CON; CU; LF; PR/AU; INC; INA; V; PO	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2831	J.F.A. Adams, "Substitutes for opium in chronic disease," Boston Medical and Surgical Journal 121 (1889): 351-56					AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2832	Jan R. McTavish, "Aspirin in Germany: The Pharmaceutical Industry and the Pharmaceutical Profession," Pharmacy in History 29 (1987): 103-115					AU; H; R; PRE; CON; CU; LF; PR/AU; INC; INA; V; PO	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2833	John C. McWilliams, The Protectors: Harry J. Anslinger and the Federal Bureau of Narcotics, 1930-1962 (Newark: University of Delaware Press, 1990)					AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2834	John Phillips Street, "The Patent Medicine Situation," American Journal of Public Health 7 (1917): 1037-38					AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2835	John Temple, American Pain: How a Young Felon and His Ring of Doctors Unleashed America's Deadliest Drug Epidemic (Guilford, Conn.: LP Press, 2015), 51-53					Preemption; AU; H; R; PRE; CON; CU; LF; PR/AU; INC; INA; V; PO	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2836	Kolb, Drug Addiction; Yesterday's Addicts: American Society and Drug Abuse, 1865-1920, ed. H. Wayne Morgan (Norman: University of Oklahoma Press, 1974)					AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2837	Lawrence Kolb, Drug Addiction: A Medical Problem (Springfield, Ill.: Charles C. Thomas, 1962), 51					AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-2838	Louis Goodman and Alfred Gilman, The Pharmacological Basis of Therapeutics: A Textbook of Pharmacology, Toxicology and Therapeutics for Physicians and Medical Students (New York: Macmillan, 1941), 217-221, quotations p. 217					AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2839	M.I. Wilbert, "Efforts to Curb the Use of Narcotic Drugs," Public Health Reports 30 (1915): 893-923					AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2840	McKesson and Robbins, Illustrated Catalogue of Druggists Sundries, Fancy Goods, Surgical Instruments, Sponges, Charmois, etc. (New York: Daniel G. F. Class, 1883), 137.					AU; R; PRE; LF; PR/AU; CON; INC; H; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901
S-2841	Meier, Pain Killer, 102-103					Nuisance Statute's Safe-harbor; AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2842	Mitchell to House Speaker John W. McCormack, July 15, 1969, "Comprehensive Drug Abuse Prevention and Control Act," vertical files, Drug Enforcement Administration Library, Arlington, Va., (quote) and Kenneth C. Baumgartner and Michael X. Morrell, "Pharmaceutical Industry Regulation by the Department of Justice," Syracuse Law Review 23 (1972): 203-205 (Schedule II procedures). The timeline and summaries draw on					AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2843	National publicity, e.g., James M. Markham, "Methadone Found Rising as a Killer: Overdose Deaths Here and in Capital Up Sharply," New York Times, March 14, 1972, p. 48.					H; R; PRE; AU; LF; PR/AU; CON; INC; IC; INA; V; PO	12 O.S. 2401, 2402; 12 O.S. 2802

S-2844	Office of Public Affairs, Department of Justice, "McKesson Agrees to Pay Record \$10 Million Settlement for Failure to Report Suspicious Orders of Pharmaceutical Drugs," press release, January 17, 2017, https://www.justice.gov/opa/pr/mckesson-agrees-pay-record-150-million-settlement-failure-report-suspicious-orders .					R; PRE; CON; CU; AU; H; PRE; LF; PR/AU; INC; INA; V; PO	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2845	Oscar C. Young, "On the Use of Opiates, Especially Morphine," <i>Medical News</i> 80 (1902): 154.					AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2846	Paul Starr, <i>The Social Transformation of American Medicine</i> (New York: Basic Books, 1982), chaps. 1-2, income statistics pp. 84-85; Courtwright, <i>Dark Paradise</i> , 50-51					AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2847	Randal D. France, K. Ranga Rama Krishnan, and Ananth N. Manepalli, "Analgesics in Chronic Pain," in <i>Chronic Pain</i> , ed. Randal D. France and K. Ranga Rama Krishnan (Washington, D.C.: American Psychiatric Press, 1988), 438					AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2848	Richard W. Hanson and Kenneth E. Gerber, <i>Coping with Chronic Pain: A Guide to Patient Self- Management</i> (New York: Guilford, 1990), 37 (quotation).					AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2849	Sam Quinones, <i>Dreamland: The True Tale of America's Opiate Epidemic</i> (New York: Bloomsbury Press, 2016), 94 (Stanton).					AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2850	Samuel Hopkins Adams, <i>The Great American Fraud</i> , 4th ed. (Chicago: Press of the American Medical Association, 1907)					AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-2851	Statutes at Large, 1970-1971, vol. 84, part 1 (Washington, D.C.: Government Printing Office, 1971), public law 91-513						AU; H; R; PRE; LF; PR/AU; CON; INA; V; PO; T-MIL-1, 9; J-MIL-1, 12	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2852	T.D. Crothers, "Medicolegal Relations of Opium Inebriety and the Necessity for Legal Recognition," Journal of the American Medical Association, hereafter JAMA, 35 (1900): 413						AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2853	T.J. Happel, "The Opium Curse and Its Prevention," Medical and Surgical Reporter 72 (1895): 728; Bomyge to Hamilton Wright, August 12, 1908, box 29, USIOC						AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2854	Thomas S. Blair, "Is Opium the 'Sheet-Anchor of Treatment'?" American Journal of Clinical Medicine 26 (1919): 831						AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; SUM	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2855	U.S. Department of Justice, Summary of Drug Control Actions Under the Controlled Substances Act of 1970 (Washington, D.C.: DEA Office of Compliance and Regulatory Affairs, 1977).						AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2856	Virgil G. Eaton, "How the Opium Habit is Acquired," Popular Science Monthly 33 (1888): 665 (Boston)						AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2857	Walter F. Boggess, "Morphinism," Medical Age 17 (1899): 883						AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2858	William A. Greene, "Hypodermic Administration of Medical Agents," Atlanta Medical and Surgical Journal 8 (1867): 97, all italicization and capitalization thus						AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-2859	William P. Millay to Hamilton Wright, August 24, 1908, box 29, and "Boston Notes" (TS, 1908), no pp., quoting Mr. Carter of Carter, Carter, & Meigs, box 43, both Records of the United States Delegation to the International Organization and Conference (hereafter USIOC), Record Group 43, National Archives, Washington, D.C. Sales				AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2860	William S. Burroughs, "Letter from a Master Addict to Dangerous Drugs," British Journal of Addiction 53 (1957): 119-120, and Burroughs to Ginsberg, June 16, 1954, Letters of William Burroughs, ed. Harris, 215. Though the article publication date is January 1957, Burroughs composed the letter on August 3, 1956, hence two years				AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2861	First edition cover of Eugene O'Neill's Long Day's Journey into Night, 1956, https://en.wikipedia.org/wiki/Long_Day%27s_Journey_into_Night				AU; R; PRE; LF; PR/AU; CON; INC; H; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901
S-2862	Mary "Ella" O'Neill, morphine addict. Photo: Irish America, https://irishamerica.com/2015/10/a-lon				AU; R; PRE; LF; PR/AU; CON; INC; H; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901
S-2863	Katharine Hepburn as Mary Tyrone, Long Day's Journey into Night, 1962. Photo: http://worldscinema.org/2018/05/sidney-lumet-long-days-journey-into-night-1962/				AU; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU; SUM	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901

S-2864	<p>Oklahoma State Capital, (Guthrie, OK), October 9, 1897, p. 4. Oklahoma State Historical Society, https://gateway.ohistory.org/ark:/67531/metaidc275703/m1/5/zoom/?resolution=2&lat=3140&lon=2132</p> <p>Carter Express (Carter, OK), December 28, 1923, p. 4. Oklahoma Historical Society, https://gateway.ohistory.org/ark:/67531/metaidc957053/m1/4/?q=carter%20oklahoma%20aspirin</p>								H; R; PRE; AU; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2802	
S-2865	<p>Advertisement for Mrs. Winslow's Soothing Syrup. "This product was for teething children and contained morphine. Card features a mother in bed with her children. She is reading a newspaper advertisement for Mrs. Winslow's Soothing Syrup." Source: National Library of Medicine, https://collections.nlm.nih.gov/catalog/nlm:nlmuid-101402395-img</p>								H; R; PRE; AU; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2802	
S-2866	<p>https://www.google.com/search?q=hydermic+syringe+nineteenth+century&client=firefox-b-1-d&source=lnms&tbn=isch&sa=X&ved=0ahUKEwilh8r1u-bhAhUKRKDKHZXB4MQ_AUIDigB&biw=1536&bih=749#imgrc=nmck9qmf347NgM:Illustrationcriticizingexcessiveuseofopiumtopacifybabies,InsidetheStoryofAmerica's19thCenturyOpiateAddiction</p>								PRE; CON; CU; AU; R; LF; PR/AU; INC; H; INA; V; PO	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901	
S-2867										PRE; CON; CU; AU; R; LF; PR/AU; INC; H; INA; V; PO	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901

S-2868	<p>Drawing from diary of Alfred Bellard, National Library of Medicine Exhibition, https://www.nlm.nih.gov/exhibition/ifeandlimb/honorableescars.html Civil War trauma led to at least some cases of postbellum addiction when chronic pain treated with opiates.</p>							AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2869	<p>Private George W. Lemon, from George A. Otis, Drawings, Photographs and Lithographs Illustrating the Histories of Seven Survivors of the Operation of Amputation at the Hipjoint, During the War of the Rebellion, Together with Abstracts of these Seven Successful Cases, 1867 National Library of Medicine, https://www.nlm.nih.gov/exhibition/ifeandlimb/maimedmen.html</p>							AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2870	<p>New York City Opium Den, 1881 https://collections.nlm.nih.gov/catalog/nlm:nlmuid-101392816-img</p>							AU; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU; T-MIL-1, 6	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901
S-2871	<p>http://www.loc.gov/pictures/item/2005693234/ "Death's laboratory—the patent medicine trust. Palatable poison for the people." 1905 print from the Library of Congress, Prints and Photographs Division</p>							AU; R; PRE; CON; CU; LF; PR/AU; INC; H; INA; V; PO	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901
S-2872	<p>Collection of Strong Museum, Rochester New York. Cough syrup Maker forced to divulge dangerous drug contents.</p>							AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2873	<p>Culver (Ind.) Citizen, March 19, 1908, p. 5. Source: National Library of Medicine, History of Medicine Division. Post Pure Food and Drug Act emphasis on treatments that avoided narcotics.</p>							H; R; PRE; AU; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2802

S-2874	<p>The Practical Druggist and Review of Reviews, v.5, no. 5 May 1899, advertisement for heroin, https://www.atlasobscura.com/articles/narcotics-in-medicine. Heroin advertised as a specific, not a cure-all.</p> <p>https://www.dailymail.co.uk/health/article-5288077/Heroin-cough-cures-yesterday-revealed.html, 1901 advertisement for heroin in the treatment of cough.</p>							<p>AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU</p>	<p>12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802</p>
S-2875	<p>National Library of Medicine, Digital collections, https://collections.nlm.nih.gov/bookviewer?PID=nlm:nlmuid-09310560R-bk#page/6/mode/2up. Oklahoma followed FBN and CDAN's suit in 1949, declaring the synthetic amiodone (methadone) to be a narcotic drug controlled by national and state laws.</p>							<p>AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU</p>	<p>12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802</p>
S-2876	<p>https://prisonphotography.org/tag/narcotic-farm/, opening of federal narcotic farm at Lexington in 1935—political cartoon commemorating the event.</p>							<p>AU; H; R; PRE; CON; CU; LF; PR/AU; INC; INA; V; PO</p>	<p>12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802</p>
S-2877	<p>"A bottle of laudanum, a highly addictive liquid preparation of opium widely used as a painkiller and sleep aid in the late 19th century," NYT, May 19, 2018, image courtesy Country Doctor Museum, East Carolina University, https://www.nytimes.com/2018/05/19/opinion/sunday/opioid-epidemic-history.html.</p>								
S-2878								<p>H; R; PRE; AU; LF; PR/AU; CON; INC; INA; V; PO; CU</p>	<p>12 O.S. 2401, 2402; 12 O.S. 2802</p>

S-2879	<p>Mangum Sun-Monitor. (Mangum, Okla.), Vol. 23, No. 45, Ed. 1 Thursday, July 17, 1913, p. 7. Source: Oklahoma Historical Society, https://gateway.ohistory.org/ark:/67531/metadc285338/m1/7/?q=morphine</p> <p>Vinita Daily Chieftain (Vinita, OK), March 13, 1907, p. 2. Oklahoma Historical Society, https://gateway.ohistory.org/ark:/67531/metadc77367/m1/2/zoom/?q=drug%20laws&resolution=6&lat=3526.5&lon=2364.5</p>	<p>H; R; PRE; CON; CU; AU; LF; PR/AU; INC; INA; V; PO</p>	<p>12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2802</p>
S-2880	<p>The Enid Daily Eagle (Enid, Okla.), Vol. 15, No. 103, Ed. 1 Friday, May 19, 1916 Page 2. Source: Oklahoma Historical Society, https://gateway.ohistory.org/ark:/67531/metadc826074/m1/1/?q=%22arrsted%20for%20morphine%22. Doctor and railroad clerk arrested in diversion conspiracy to circumvent the Harrison Narcotic Act.</p>	<p>H; R; PRE; CON; CU; AU; LF; PR/AU; INC; INA; V; PO</p>	<p>12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2802</p>
S-2881	<p>"Opium Tax Certificate for P.M. Mark Medicine Company," Minnesota, 1915. Government regulation and taxation in the twentieth century helped to control the distribution of addictive substances. Courtesy of the East Polk Heritage Center via Minnesota Digital Library. https://dp.la/exhibitions/patent-medicine/1860-1920/opiates-alcohol-herbs?item=1295</p>	<p>AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU</p>	<p>12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802</p>

S-2883	Oklahoma News (Oklahoma City), March 10, 1916, p. 2. Oklahoma Historical Society: https://gateway.okhistory.org/ark:/67531/metadc859567/m1/1/?q=paregoric						H; R; PRE; AU; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2802
S-2884	El Reno Daily Tribune (El Reno, OK), May 16, 1939, p. 1. Oklahoma Historical Society, https://gateway.okhistory.org/ark:/67531/metadc921160/m1/1/zoom/?q=%22narcotic%20addicts%22&resolution=6&lat=4997.999999&lon=-3237.5000000000002						H; R; PRE; CON; CU; AU; LF; PR/AU; INC; INA; V; PO	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2802
S-2885	https://collections.nlm.nih.gov/ext/dw/25922610R/PDF/25922610R.pdf						H; R; PRE; AU; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2802
S-2886	James M. Markham, "Methadone Found Rising as a Killer: Overdose Deaths Here and in Capital Up Sharply," New York Times, March 14, 1972, p. 48. https://timesmachine.nytimes.com/timesmachine/1972/03/14/issue.htm						H; R; PRE; AU; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2802
S-2887	Photographs used for an April 24, 1972, story in the Daily Oklahoman. Caption: "Robert L. Bowen, left, and Kenneth Wiley, both of Meeker, leave the federal building Monday after being charged with selling 3.8 grams of imported heroin to an undercover agent." Source: Oklahoma Historical Society: https://gateway.okhistory.org/ark:/67531/metadc244844/?q=heroin%20date%3A1969-1974						AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-2893	<p>http://www.patrickcomerford.com/2013/03/with-saints-in-lent-43-charles-henry.html Charles Henry Brent, architect of international narcotic control.</p> <p>https://www.findagrave.com/memorial/155410489/henry-parr-hynson#view-photo=132426518. Henry P. Hynson, authority on pharmaceutical trade interviewed by a federal official in 1908 concerning narcotic prescription and use trends. Quoted in "Baltimore Notes," USIOC.</p>							AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2894	<p>Harry Anslinger, head of the Federal Bureau of Narcotics, 1930-1962, from the Hoover Administration to the Kennedy administration. Photo sources: https://terpenesandtesting.com/cate-gory/news/who-was-harry-anslinger/ https://www.case.org/system/files/media/file/Penn%20Stater%20Harry%20Anslinger.pdf</p>							AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2895	<p>https://nihrecord.nih.gov/PDF_Archive/1960%20PDFs/19600830.pdf. Nathan Eddy, Anslinger ally who evaluated pharmaceutical claims about purported safety of new synthetic and semi-synthetic products.</p>							AU; R; PRE; LF; PR/AU; CON; INC; H; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901
S-2896	<p>https://collections.nlm.nih.gov/catalog/.nlm:nlmuid-101420707-img Photo of Dr. Lawrence Kolb, leading U.S addiction authority in the mid-twentieth century</p>							R; PRE; AU; LF; PR/AU; CON; INC; H; INA; V; PO; CU	12 O.S. 2401, 2402
S-2897								AU; R; PRE; LF; PR/AU; CON; PO; CU; T-MIL-1, 6, 9; J-MIL-1, 8, 12	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901

S-2898	National Academies of Sciences, Engineering, and Medicine. 2017. Pain Management and the Opioid Epidemic: Balancing Societal and Individual Benefits and Risks of Prescription Opioid Use . Washington, DC: The National Academies Press. doi: https://doi.org/10.17226/24781				H; R; PRE; AU; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2802
S-2899	The ASAM Criteria: Treatment Criteria for Addictive, Substance-Related, and Co-Occurring Conditions. Access: https://www.asam.org/resources/publications				H; R; PRE; AU; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2802
S-2900	U.S. Department of Health and Human Services (HHS), Office of the Surgeon General, Facing Addiction in America: The Surgeon General's Report on Alcohol, Drugs, and Health. Washington, DC: HHS, November 2016. Access: https://www.addiction.surgeongeneral.gov/sites/default/files/surgeon-general-s-report.pdf				H; R; PRE; AU; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2802
S-2901	Substance Abuse and Mental Health Services Administration. Medications for Opioid Use Disorder. Treatment Improvement Protocol (TIP) Series 63, Full Document. HHS Publication No. (SMA) 18- 5063FULLDOC. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2018. Access: https://store.samhsa.gov/system/files/sma18-5063fulldoc_0.pdf				First Amendment; H; R; PRE; AU; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2802

S-2902	Centers for Disease Control and Prevention. Evidence-Based Strategies for Preventing Opioid Overdose: What's Working in the United States. National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, 2018. Accessed [date] from http://www.cdc.gov/drugoverdose/pdf/f/pubs/2018-evidence-based-strategies.pdf					H; R; PRE; AU; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2802
S-2903	Johns Hopkins Bloomberg School of Public Health. The Opioid Epidemic: From Evidence to Impact. Baltimore: Johns Hopkins Bloomberg School of Public Health; October 2017. Access: https://www.jhsph.edu/events/2017/americas-opioid-epidemic/report/2017-JohnsHopkins-Opioid-digital.pdf					AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2904	Guide to Community Preventive Services. Tobacco Use and Secondhand Smoke Exposure: Quitline Interventions; accessed: December 2, 2013					H; R; PRE; AU; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2802
S-2905	Children and Family Futures. National Strategic Plan for Family Drug Courts, March 2017. https://www.ddcf.org/globalassets/child-well-being/17-0502-cff-national-fdc-strategic-plan.pdf					First Amendment; AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-2906	Madras BK, Compton WM, Avula D, Stegbauer T, Stein JB, Clark HW. Screening, brief interventions, referral to treatment (SBIRT) for illicit drug and alcohol use at multiple healthcare sites: comparison at intake and 6 months later. Drug Alcohol Depend (2009) 99:280-9510.1016/j.drugalcdep.2008.08.003					R; PRE; CON; CU; H; PRE; AU; LF; PR/AU; INC; INA; V; PO	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2802
S-2907	Spoth R., Trudeau L, Shin C., Ralston E., Redmond C., Greenberg M., Feinberg M. (2013). Longitudinal effects of universal preventive intervention on prescription drug misuse: three randomized controlled trials with late adolescents and young adults. American Journal of Public Health					PRE; CON; CU; AU; H; R; LF; PR/AU; INC; INA; V; PO	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2908	Feigelman, W., Jordan, J. R., & Gorman, B. S. (2011). Parental Grief after a Child's Drug Death Compared to other Death Causes: Investigating a Greatly Neglected Bereavement Population. OMEGA - Journal of Death and Dying, 63(4), 291-316. https://doi.org/10.2190/OM.63.4.a					PRE; CON; CU; AU; H; R; LF; PR/AU; INC; INA; V; PO	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2909	Neonatal Abstinence Syndrome: How States Can Help Advance the Knowledge Base for Primary Prevention and Best Practices of Care, 2014. Association of State and Territorial Health Officials. http://www.astho.org/prevention/nas/neonatal-abstinence-report/					PRE; CON; CU; AU; H; R; LF; PR/AU; INC; INA; V; PO	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-2910	Opioid use and opioid use disorder in pregnancy. Committee Opinion No. 711. American College of Obstetricians and Gynecologists. Obstet Gynecol 2017; 130:e81-94. https://www.acog.org/-/media/Committee-Opinions/Committee-on-Obstetric-Practice/co711.pdf?dmc=1&ts=20190304T1614387975							PRE; CON; CU; AU; H; R; LF; PR/AU; INC; INA; V; PO	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2911	Wright, Tricia E. The role of screening, brief intervention, and referral to treatment in the perinatal period American Journal of Obstetrics & Gynecology , Volume 215 , Issue 5 , 539 - 547et al.							PRE; CON; CU; AU; H; R; LF; PR/AU; INC; INA; V; PO	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2912	Substance Abuse and Mental Health Services Administration. Clinical Guidance for Treating Pregnant and Parenting Women with Opioid Use Disorder and Their Infants, 2018. https://store.samhsa.gov/system/files/sma18-5054.pdf							PRE; CON; CU; AU; H; R; LF; PR/AU; INC; INA; V; PO	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2913	Tracking PDMP Enhancement: The Best Practices Checklist. 2017. Brandeis University, The Heller School for Social Policy and Management, The Prescription Drug Monitoring Program Training and Technical Assistance Center. Access: https://www.pdmassist.org/pdf/Resources/2016_Best_Practice_Checklist_Report_20170228.pdf							AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-2914	Clark T, Eadie J, Knue, P, et al. Prescription Drug Monitoring Programs: An Assessment of the Evidence for Best Practices. External Link. Waltham, MA: Prescription Drug Monitoring Center of Excellence. Brandeis University; 2012							AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2915	US Department of Health and Human Services. ASPE Issue Brief: Opioid Abuse in the U.S. and HHS Actions to Address Opioid-Drug Related Overdoses and Deaths. External Link. Washington, DC: US Department of Health and Human Services; 2015							AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2916	Jilani SM, Frey MT, Pepin D, et al. Evaluation of State-Mandated Reporting of Neonatal Abstinence Syndrome — Six States, 2013–2017. MMWR Morb Mortal Wkly Rep 2019; 68:6–10. DOI: http://dx.doi.org/10.15585/mmwr.mm6801a2 External							PRE; CON; CU; AU; H; R; LF; PR/AU; INC; INA; V; PO	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2917	Porter J, Jick H. 1980, Jan 10. Addiction rare in patients treated with narcotics. N Engl J Med. 302(2):123.							AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2918	Leung PTM, Macdonald EM, Stanbrook MB, Dhalla IA, Juurlink DN. 2017, Jun 1. A 1980 Letter on the Risk of Opioid Addiction. N Engl J Med. 376(22):2194-2195.							AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2919	Portenoy RK, Foley KM. Chronic use of opioid analgesics in non-malignant pain: report of 38 cases. 1986. Pain. May;25(2):171-86. 0							AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2920	Melzack R. 1990. The tragedy of needless pain. Sci Am. 262(2):27-33.							AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-2921	Portenoy RK. 1990 Chronic opioid therapy in nonmalignant pain. J Pain Symptom Manage (1 Suppl):S46-62.							AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2922	Max MB. 1990 Improving outcomes of analgesic treatment: is education enough? Ann Intern Med. 113(11):885-889							AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2923	Bloomquist ER. 1963 Aug. The addiction potential of oxycodone (Percodan). Calif Med. 99:127-30.							AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2924	Skolnick P. The Opioid Epidemic: Crisis and Solutions. Annu Rev Pharmacol Toxicol. 2017 Oct 2. [Epub ahead of print]							AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2925	Dart RC, Surratt HL, Cicero TJ, Parrino MW, Severtson SG, et al. 2015. Trends in opioid analgesic abuse and mortality in the United States. N. Engl. J. Med. 372:241-48							AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2926	Cicero TJ, Ellis MS, Surratt HL, Kurtz SP. 2014. The changing face of heroin use in the United States: a retrospective analysis of the past 50 years. JAMA Psychiatry 71:821-26.							AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2927	The United States Senate Committee on Finance Website. http://www.finance.senate.gov/chairmans-news/baucus-grassley-seek-diagnosis-about-opioid-manufacturers-ties-to-medical-groups .							AU; H; R; PRE; CON; CU; Incomplete Document; LF; PR/AU; INC; INA; V; PO	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2928	Lin DH, Lucas E, Murimi IB, Kolodny A, Alexander GC. 2017 Mar 1. Financial Conflicts of Interest and the Centers for Disease Control and Prevention's 2016 Guideline for Prescribing Opioids for Chronic Pain. JAMA Intern Med. 177(3):427-428.							AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-2929	Cicero TJ, Kurtz SP, Surratt HL, Ibanez GE, Ellis MS, Levi-Minzi MA, Inciardi JA. 2011 Multiple Determinants of Specific Modes of Prescription Opioid Diversion. J Drug Issues. 41(2):283-304					AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2930	Campbell JN. APS 1995 Presidential address. Pain Forum. 1996;5:85-8.					AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2931	Veterans Health Administration. Pain as the 5th Vital Sign Toolkit. 2000. https://www.va.gov/PAINMANAGEMENT/docs/Pain_As_the_5th_Vital_Sign_Toolkit.pdf .					AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2932	Phillips DM. 2000, Jul 26. JCAHO pain management standards are unveiled. Joint Commission on Accreditation of Healthcare Organizations. JAMA. 284(4):428-9.					AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2933	Baker DW. 2017, Mar 21. History of The Joint Commission's Pain Standards: Lessons for Today's Prescription Opioid Epidemic. JAMA. 317(11):1117-1118.					AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2934	Chhabra N, Leikin JB. 2017, Jul 4. The Joint Commission and the Opioid Epidemic. JAMA. 318(1):91-92.					AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2935	Baker DW. 2017, Jul 4. The Joint Commission and the Opioid Epidemic-Reply. JAMA. 318(1):92					AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2936	https://www.fsmb.org/Media/Default/PDF/FSMB/Advocacy/1998_grpol_Pain_Management_Guide_lines.pdf					AU; H; R; PRE; CON; CU; Incomplete Document; LF; PR/AU; INC; INA; V; PO	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2937	The Joint Commission. Pain management. https://www.jointcommission.org/topics/pain_management.aspx .					AU; H; R; PRE; CON; CU; Incomplete Document; LF; PR/AU; INC; INA; V; PO	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-2938	Pain Management and the Opioid Epidemic: Balancing Societal and Individual Benefits and Risks of Prescription Opioid Use, The National Academies Press. http://nationalacademies.org/hmd/Reports/2017/pain-management-and-the-opioid-epidemic.aspx .						H; R; PRE; AU; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2802
S-2939	Statement from FDA Commissioner Scott Gottlieb, M.D., on National Academies of Sciences, Engineering, and Medicine report on pain management and prescription opioid abuse. 2017, July 13. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm566958.htm .						H; R; PRE; AU; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2802
S-2940	https://www.cdc.gov/drugoverdose/data/prescribing.html						H; R; PRE; AU; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2802
S-2941	Daubresse M, Chang H, Yu Y, Viswanathan S, et al. 2013. Ambulatory diagnosis and treatment of nonmalignant pain in the United States, 2000 – 2010. Medical Care 51(10): 870-878. http://dx.doi.org/10.1097/MLR.0b013e3182a95d86						AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2942	Madras BK. 2017, May 1. The Surge of Opioid Use, Addiction, and Overdoses: Responsibility and Response of the US Health Care System. JAMA Psychiatry. 74(5):441-442.						AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2943	Chiu AS, Healy JM, DeWane MP, Longo WE, Yoo PS. 2017, Jul 10. Trainees as Agents of Change in the Opioid Epidemic: Optimizing the Opioid Prescription Practices of Surgical Residents. J Surg Educ. pii: S1931-7204(17)30157-5.						AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-2944	Madras BK. 2010 Feb. Office of National Drug Control Policy: a scientist in drug policy in Washington, DC. Ann N Y Acad Sci. 1187:370-402.						AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2945	Madras BK, Compton WM, Avula D, Stegbauer T, Stein JB, Clark HW. 2009, Jan 1. Screening, brief interventions, referral to treatment (SBIRT) for illicit drug and alcohol use at multiple healthcare sites: comparison at intake and 6 months later. Drug Alcohol Depend. 99(1-3):280-95.						AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2946	Gupta A, Lee LK, Mojica JJ, Nairizi A, George SJ. 2014, Sep-Oct. Patient perception of pain care in the United States: a 5-year comparative analysis of hospital consumer assessment of health care providers and systems. Pain Physician. 17(5):369-77.						AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2947	Kelly S, Johnson GT, Harbison RD. 2016, Apr-Jun. "Pressured to prescribe" The impact of economic and regulatory factors on South-Eastern ED physicians when managing the drug seeking patient. J Emerg Trauma Shock. 9(2):58-63.						AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2948	O'Donnell JK, Halpin J, Mattson CL, Goldberger BA, Gladden RM. 2017. Deaths Involving Fentanyl, Fentanyl Analogs, and U-47700 — 10 States, July–December 2016. MMWR Morb Mortal Wkly Rep. ePub: 27 October 2017. DOI: http://dx.doi.org/10.15585/mmwr.mm6643e1 .						AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2949	https://www.dea.gov/divisions/hq/2016/hq100416.shtml						AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-2950	<p>Substance Abuse and Mental Health Services Administration. 2017. Results from the 2016 National Survey on Drug Use and Health: Detailed Tables. Table 1.28A and 1.28B. Retrieved from https://www.samhsa.gov/data/sites/default/files/NSDUH-DetTabs-2016/NSDUH-DetTabs-2016.pdf, accessed on October 26, 2017.</p>			<p>AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU</p>	<p>12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802</p>
S-2951	<p>Han B, Compton WM, Blanco C, Crane E, Lee J, Jones CM. 2017. Prescription Opioid Use, Misuse, and Use Disorders in U.S. Adults: 2015 National Survey on Drug Use and Health. <i>Ann Intern Med</i> 167(5):293-301.</p>			<p>AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU</p>	<p>12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802</p>
S-2952	<p>Center for Behavioral Health Statistics and Quality. (2016). Key substance use and mental health indicators in the United States: Results from the 2015 National Survey on Drug Use and Health (HHS Publication No. SMA 16-4984, NSDUH Series H-51). Retrieved from http://www.samhsa.gov/data/.</p>			<p>AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU</p>	<p>12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802</p>
S-2953	<p>Substance Abuse and Mental Health Services Administration. 2017. Results from the 2016 National Survey on Drug Use and Health: Detailed Tables. Section 1 Tables and Table 5.17A. Retrieved from https://www.samhsa.gov/data/sites/default/files/NSDUH-DetTabs-2016/NSDUH-DetTabs-2016.pdf, accessed on October 26, 2017.</p>			<p>AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU</p>	<p>12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802</p>

S-2954	Substance Abuse and Mental Health Services Administration. 2017. Results from the 2016 National Survey on Drug Use and Health: Detailed Tables. Section 5 Tables. Retrieved from https://www.samhsa.gov/data/sites/default/files/NSDUH-DetTabs-2016/NSDUH-DetTabs-2016.pdf , accessed on October 26, 2017						AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2955	McCabe SE, West BT, Morales M, Cranford JA, Boyd CJ. 2007. Does early onset of non-medical use of prescription drugs predict subsequent prescription drug abuse and dependence? Results from a national study. <i>Addiction</i> . 102(12):1920-30.						AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2956	Sullivan MD, Edlund MJ, Zhang L, Unutzer J, Wells KB. 2006. Association between mental health disorders, problem drug use, and regular prescription opioid use. <i>Arch Intern Med</i> . 166(19):2087-93.						AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2957	Barry DT, Goulet JL, Kerns RK, Becker WC, Gordon AJ, Justice AC, Fiellin DA. 2011, May. Nonmedical use of prescription opioids and pain in veterans with and without HIV. <i>Pain</i> . 152(5):1133-8.						AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2958	Galanter M, Dermatis H, Sampson C. 2014. Narcotics anonymous: a comparison of military veterans and non-veterans. <i>J Addict Dis</i> . 33(3):187-95.						AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2959	Kaltenbach K, Berghella V, Finnegan L. 1998. Opioid dependence during pregnancy. Effects and management. <i>Obstet Gynecol Clin North Am</i> 25(1):139-51.						PRE; CON; CU; AU; H; R; LF; PR/AU; INC; INA; V; PO	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-2960	Becker WC, Sullivan LE, Tetrault JM, Desai RA, Fiellin DA. 2008. Non-medical use, abuse and dependence on prescription opioids among U.S. adults: psychiatric, medical and substance use correlates. <i>Drug Alcohol Depend</i> 94(1-3):38-47.					AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2961	Substance Abuse and Mental Health Services Administration. 2017. Results from the 2016 National Survey on Drug Use and Health: Detailed Tables. Table 1.28A and 1.28B. Retrieved from https://www.samhsa.gov/data/sites/default/files/NSDUH-DETabs-2016/NSDUH-DETabs-2016.pdf , accessed on October 26, 2017.					AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2962	Wu LT, Zhu H, Swartz MS. 2016, Dec 1. Treatment utilization among persons with opioid use disorder in the United States. <i>Drug Alcohol Depend</i> . 169:117-127.					AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2963	Katzman JG, Fore C, Bhatt S, Greenberg N, Griffin Salvador J, Comerci GC, Camarata C, Marr L, Monette R, Arora S, Bradford A, Taylor D, Dillow J, Karol S. 2016, Aug. Evaluation of American Indian Health Service Training in Pain Management and Opioid Substance Use Disorder. <i>Am J Public Health</i> . 106(8):1427-9.					AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2964	O'Donnell JK, Halpin J, Mattson CL, Goldberger BA, Gladden RM. Deaths Involving Fentanyl, Fentanyl Analogs, and U-47700 — 10 States, July–December 2016. <i>MMWR Morb Mortal Wkly Rep</i> . ePub: 27 October 2017. DOI: http://dx.doi.org/10.15585/mmwr.mm6643e1					AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-2965	Madras BK. 2017. The Growing Problem of New Psychoactive Substances (NPS). <i>Curr Top Behav Neurosci</i> 32:1-18.							AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2966	Logan BK, Mohr ALA, Friscia M, Krotulski AJ, Papsun DM, Kacinko SL, Ropero-Miller JD, Huestis MA. 2017. Reports of adverse events associated with use of novel psychoactive substances, 2013-2016: A review. <i>J Anal Toxicol</i> 41(7):573-610.							AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2967	Cicero TJ, Ellis MS, Kasper ZA. 2017. Aug. 1. Increases in self-reported fentanyl use among a population entering drug treatment: The need for systematic surveillance of illicitly manufactured opioids. <i>Drug Alcohol Depend.</i> 177:101-103.							AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2968	Klar SA, Brodtkin E, Gibson E, Padhi S, Prety C, Green C, Lee V. Notes from the Field: Fentanyl- Fentanyl Overdose Events Caused by Smoking Contaminated Crack Cocaine - British Columbia, Canada, July 15-18, 2016. <i>MMWR Morb Mortal Wkly Rep.</i> 2016 Sep 23;65(37):1015-1016.							AU; H; R; PRE; CON; CU; LF; PR/AU; INC; INA; V; PO	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2969	Fabregat-Safont D, Carbón X, Ventura M, Formis I, Guillamón E, Sancho JV, Hernández F, Ibáñez M. 2017. Updating the list of known opioids through identification and characterization of the new opioid derivative 3,4-dichloro-N-(2-(diethylamino)cyclohexyl)-N-methylbenzamide (U-49900). <i>Sci Rep</i> 7(1):6338.							AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-2970	Zawilska JB. 2017. An Expanding World of Novel Psychoactive Substances: Opioids. <i>Front Psychiatry</i> . 2017 Jun 30;8:110.						AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2971	Fleming SW, Cooley JC, Johnson L, Frazee CC, Domanski K, Kleinschmidt K, Garg U. 2017 Apr 1. Analysis of U-47700, a Novel Synthetic Opioid, in Human Urine by LC-MS-MS and LC-QToF. <i>J Anal Toxicol</i> . 41(3):173-0.						AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2972	Prekupec MP, Mansky PA, Baumann MH. 2017 Jul/Aug. Misuse of Novel Synthetic Opioids: A Deadly New Trend. <i>J Addict Med</i> . 11(4):256-265.						AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2973	Ventura L, Carvalho F, Dinis-Oliveira RJ. 2017. Opioids in the frame of new psychoactive substances network: A complex pharmacological and toxicological issue. <i>Curr Mol Pharmacol</i> [Epub ahead of print].						AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2974	Soares JX, Alves EA, Silva AMN, de Figueiredo NG, Neves JF, Cravo SM, Rangel M, Netto ADP, Carvalho F, inis-Oliveira RJ, Afonso CM. 2017. Street-like synthesis of Krokodil Results in the formation of an enlarged cluster of known and new morphinans. <i>Chem Res Toxicol</i> 30(8):1609-1621.						AU; H; R; PRE; CON; CU; LF; PR/AU; INC; INA; V; PO	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2975	Substance Abuse and Mental Health Services Administration. 2017. Results from the 2016 National Survey on Drug Use and Health: Detailed Tables. Table 1.28A. Retrieved from https://www.samhsa.gov/data/sites/default/files/NSDUH-DetTabs-2016/NSDUH-DetTabs-2016.pdf on October 25, 2017.						AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-2976	Cicero TJ, Ellis MS, Kasper ZA. 2017 Feb. Psychoactive substance use prior to the development of iatrogenic opioid abuse: A descriptive analysis of treatment-seeking opioid abusers. <i>Addict Behav.</i> 65:242-244.						AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2977	Jarlenski M, Barry CL, Gollust S, Graves AJ, Kennedy-Hendricks A, Kozhimannil K. 2017 Aug. Polysubstance Use Among US Women of Reproductive Age Who Use Opioids for Nonmedical Reasons. <i>Am J Public Health.</i> 107(8):1308-1310.						AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2978	McCabe SE, West BT, Jutkiewicz EM, Boyd CJ. 2017 Sep. Multiple DSM-5 substance use disorders: A national study of US adults. <i>Hum Psychopharmacol.</i> 32(5). [e-pub July 2017]						AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2979	Han B, Compton WM, Jones CM, Cai R. 2015. Nonmedical prescription opioid use and use disorders among adults aged 18 through 64 years in the United States, 2003-2013. <i>JAMA</i> 314(14):1468-78.						AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2980	Carlson RG, Nahhas RW, Martins SS, Daniulaityte R. 2016. Predictors of transition to heroin use among initially non-opioid dependent illicit pharmaceutical opioid users: A natural history study. <i>Drug Alcohol Depend</i> 160:127-34.						AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-2981	Comer SD, Sullivan MA, Whittington RA, Vosburg SK, Kowalczyk WJ. 2008. Abuse liability of prescription opioids compared to heroin in morphine-maintained heroin abusers. <i>Neuropsychopharmacology</i> 33(5):1179-91.						AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2982	Shah A, Hayes CJ, Martin BC. 2017. Factors influencing long-term opioid use among opioid naive patients: An examination of initial prescription characteristics and pain etiologies. <i>J Pain</i> [Epub ahead of print].						AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2983	Stumbo SP, Yarbrough BJ, McCarty D, Weisner C, Green CA. 2017. Patient-reported pathways to opioid use disorders and pain-related barriers to treatment engagement. <i>J Subst Abuse Treat</i> 73:47-54.						AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2984	Manchikanti L, Helm S II, Fellows B, et al. 2012. Opioid epidemic in the United States. <i>Pain Physician</i> 15:Suppl:ES9-38.						AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2985	Arria AM, Compton WM. 2017. Complexities in understanding and addressing the serious public health issues related to the nonmedical use of prescription drugs. <i>Addict Behav</i> 65:215-217.						AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2986	Compton WM, Jones CM, Baldwin GT. 2016. Relationship between nonmedical prescription-opioid use and heroin use. <i>N Engl J Med</i> 374(2):154-63.						AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2987	Compton WM, Jones CM, Baldwin GT. 2016. Nonmedical prescription-opioid use and heroin use. <i>N Engl J Med</i> 374(13):1296						AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-2988	Muhuri PK, Gfroerer JC, Davies C. 2013, August. Associations of nonmedical pain reliever use and initiation of heroin use in the United States. CBHSQ Data Review. Available at http://archive.samhsa.gov/data/2k13/DataReview/DR006/nonmedical-pain-reliever-use-2013.pdf .					AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2989	Al-Tayyib AA, Koester S, Riggs P. 2017. Prescription opioids prior to injection drug use: Comparisons and public health implications. Addict Behav 65:224-228.					AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2990	Compton WM, Jones CM, Baldwin GT. 2016. Relationship between nonmedical prescription-opioid use and heroin use. N Engl J Med 374(2):154-63.					AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2991	Muhuri PK, Gfroerer JC, Davies C. 2013, August. Associations of nonmedical pain reliever use and initiation of heroin use in the United States. CBHSQ Data Review. Available at http://archive.samhsa.gov/data/2k13/DataReview/DR006/nonmedical-pain-reliever-use-2013.pdf					AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2992	Cerdá M, Santaella J, Marshall BD, Kim JH, Martins SS. 2015. Nonmedical prescription opioid use in childhood and early adolescence predicts transitions to heroin use in young adulthood: A national study. J Pediatr 167(3):605-12.					AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2993	https://www.cdc.gov/vitalsigns/heroin/infographic.html#graphic					AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-2994	Cicero TJ, Ellis MS, Kasper ZA. 2017. Increased use of heroin as an initiating opioid of a abuse. Addict Behav 74:63-66.						AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2995	Cicero TJ, Ellis MS, Kasper ZA. 2017. Psychoactive substance use prior to the development of iatrogenic opioid abuse: A descriptive analysis of treatment-seeking opioid abusers. Addict Behav 65:242-244.						AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2996	Martins SS, Sarvet A, Santaella-Tenorio J, Saha T, Grant BF, Hasin DS. 2017. Changes in lifetime heroin use and heroin use disorder: Prevalence from the 2001-2002 to 2012-2013 National Epidemiologic Survey on Alcohol and Related Conditions. JAMA Psychiatry 74(5):445-455						AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2997	Cicero TJ, Ellis MS, Kasper ZA. 2017, Nov. Increased use of heroin as an initiating opioid of a abuse. Addict Behav. 74:63-66						AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2998	Hser YI, Evans E, Grella C, Ling W, Anglin D. 2015 Mar-Apr. Long-term course of opioid addiction. Harv Rev Psychiatry.23(2):76-89.						AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2999	Degenhardt L, Bucello C, Mathers B, Briegleb C, Ali H, Hickman M, McLaren J. 2011 Jan. Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies. Addiction. 106(1):32-51.						AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3000	Robins LN, Slobodyan S. 2003. Post-Vietnam heroin use and injection by returning US veterans: clues to preventing injection today. Addiction 98: 1053-60.						AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-3001	Robins LN, Davis DH, Goodwin DW. 1974. Drug use by U.S. Army enlisted men in Vietnam: a follow-up on their return home. Am J Epidemiol 99: 235-49.						AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3002	Grella CE, Lovinger K. 2011. 30-year trajectories of heroin and other drug use among men and women sampled from methadone treatment in California. Drug Alcohol Depend. 118: 251-8.						AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3003	Hser YI. 2007. Predicting long-term stable recovery from heroin addiction: findings from a 33-year follow-up study. J Addict Dis. 26: 51-60.						AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3004	Scherbaum N, Specka M. 2008. Factors influencing the course of opiate addiction. Int J Methods Psychiatr Res 17 suppl 1: S39-44.						AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3005	Waldorf D. 1983. Natural recovery from opiate addiction: some social-psychological processes of untreated recovery. J Drug Issues 13: 237-80.						AU; H; R; PRE; CON; CU; Incomplete Document; LF; PR/AU; INC; INA; V; PO	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3006	Ries R, Krupski A, West II, Maynard C, Bumgardner K, Donovan D, Dunn C, Roy-Byrne P. 2015. Correlates of opioid use in adults with self-reported drug use recruited from public safety-net primary care clinics. J Addict Med 9(5):417-26.						AU; R; PRE; LF; PR/AU; CON; INC; H; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901
S-3007	McHugh RK, Votaw VR, Bogunovic O, Karakula SL, Griffin ML, Weiss RD. 2017. Anxiety sensitivity and nonmedical benzodiazepine use among adults with opioid use disorder. Addict Behav 65:283- 288.						AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-3008	Scheidegger C, Zimmerli W. 1996. Incidence and spectrum of severe medical complications among hospitalized HIV-seronegative and HIV seropositive narcotic drug users. AIDS 10:1407-14.					AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3009	Ronan MV, Herzig SI. 2016. Hospitalizations related to opioid abuse/ dependence and associated serious infections increased sharply, 2002-12. Health Aff (Millwood) 35:832-7.					AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3010	Suryaprasad AG, White JZ, Xu F, Eichler BA, Hamilton J, Patel A, Hamdounia SB, Church DR, Barton K, Fisher C, Macomber K, Stanley M, Guilfoyle SM, Sweet K, Liu S, Iqbal K, Tohme R, Sharapov U, Kupronis BA, Ward JW, Holmberg SD. 2014, Nov 15. Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006-2012. Clin Infect Dis 59(10):1411-9.					AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3011	Fleischauer AT, Ruhl L, Rhea S, Barnes E. 2017. Hospitalizations for endocarditis and associated health care costs among persons with diagnosed drug dependence - North Carolina, 2010-2015. Morb Mortal Wkly Rep 66(22):569-573.					R; PRE; CON; CU; AU; H; PRE; LF; PR/AU; INC; INA; V; PO	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-3012	<p>Broz D, Wejnert C, Pham HT, DiNenno E, Heffelfinger JD, Cribbin M, Krishna N, Teshale EH, Paz- Bailey G. 2014 Jul 4. National HIV Behavioral Surveillance System Study Group. HIV infection and risk, prevention, and testing behaviors among injecting drug users -- National HIV Behavioral Surveillance System, 20 U.S. cities, 2009. <i>MMWR Surveill Summ.</i> 63(6):1-51.</p>						<p>AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU</p>	<p>12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802</p>
S-3013	<p>Bach AG, Jordan B, Wegener NA, Rusner C, Kornhuber M, Abbas J, Surov A. 2012. Heroin spongiform leukoencephalopathy (HSLE). <i>Clin Neuroradiol</i> 22(4):345-9.</p>						<p>AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU</p>	<p>12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802</p>
S-3014	<p>Borne J, Riascos R, Cuellar H, Vargas D, Rojas R. 2005. Neuroimaging in drug and substance abuse part II: opioids and solvents. <i>Top Magn Reson Imaging</i> 16(3):239-45.</p>						<p>AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU</p>	<p>12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802</p>
S-3015	<p>Fareed A, Kim J, Ketchen B, Kwak WJ, Wang D, Shongo-Hiango H, Drexler K. 2017. Effect of heroin use on changes of brain functions as measured by functional magnetic resonance imaging, a systematic review. <i>J Addict Dis</i> 36(2):105-116.</p>						<p>AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU</p>	<p>12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802</p>
S-3016	<p>Lefaucheur R, Lebas A, Gérardin E, Grangeon L, Ozkul-Wermester O, Aubier-Girard C, Martinaud O, Maitéte D 2017. Leucoencephalopathy following abuse of sniffed heroin. <i>J Clin Neurosci</i> 35:70-72.</p>						<p>AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU</p>	<p>12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802</p>
S-3017	<p>Corr TE, Hollenbeck CS. 2017. The economic burden of neonatal abstinence syndrome in the United States. <i>Addiction</i> 112(9):1590-1599.</p>						<p>AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU</p>	<p>12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802</p>

S-3018	Callaghan T, Crimmins J, Schweitzer RD. Children of substance-using mothers: child health engagement and child protection outcomes. J Paediatr Child Health. 2011;47(4):223-227.						R; PRE; CON; CU; AU; H; PRE; LF; PR/AU; INC; INA; V; PO	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3019	Child Welfare Information Gateway. 2016. Parental Drug Use as Child Abuse. U.S. Department of Health and Human Services, Children's Bureau. Washington, DC. Accessed at https://www.childwelfare.gov/pubPDF/fs/drugexposed.pdf on October 25, 2017.						AU; R; PRE; LF; PR/AU; CON; INC; H; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901
S-3020	Solis JM, Shadur JM, Burns AR, Hussong AM. 2012 Jun/ Understanding the diverse needs of children whose parents abuse substances. Curr Drug Abuse Rev. 5(2):135-47.						AU; H; R; PRE; CON; CU; LF; PR/AU; INC; INA; V; PO	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3021	Krueger, AB. 2017. Where Have All The Workers Gone? An Inquiry into the Decline of the U.S. Labor Force Participation Rate. Brookings Papers on Economic Activity. Accessed at https://www.brookings.edu/wp-content/uploads/2017/09/1_krueger.pdf on October 25, 2017.						AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3022	Curtis S. Florence, Chao Zhou, Feijun Luo, Likang Xu. 2016. The economic burden of prescription opioid overdose, abuse, and dependence in the United States, 2013. Medical Care 54 (10): 901						AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-3023	CDC National Center for Health Statistics. 2017. Provisional Counts of Drug Overdose Deaths, as of 8/6/2017. Accessed at https://www.cdc.gov/nchs/data/health_policy/monthly-drug-overdose-death-estimates.pdf on September 5, 2017.						R; PRE; CON; CU; AU; H; PRE; LF; PR/AU; INC; INA; V; PO	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3024	Brady JE, Giglio R, Keyes KM, DiMaggio C, Li G. 2017. Risk markers for fatal and non-fatal prescription drug overdose: a meta-analysis. <i>Inj Epidemiol</i> 4(1):24.						AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3025	Data on facilities from the Substance Abuse and Mental Health Services Administration. National Survey of Substance Abuse Treatment Services Information on the Behavioral Health Treatment Services Locator, available at https://findtreatment.samhsa.gov/ . Extracted by ONDCP on February 10, 2016; county levels of urbanization are from the National Center for Health Statistics classification.						AU; H; R; PRE; CON; CU; Incomplete Document; LF; PR/AU; INC; INA; V; PO	12 O.S. 2401, 2402; 12 O.S. 2602; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3026	ASAM. 2005. Principles for Outcome Evaluation in the Treatment of Substance-Related Disorders: a Joint AMBHA-ASAM Statement. Retrieved from https://www.asam.org/docs/default-source/public-policy-statements/1outcome-evaluation-1-012.pdf?sfvrsn=0						AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3027	Gibson, A., et al. 2008. Exposure to opioid maintenance treatment reduces long-term mortality. <i>Addiction</i> 103(3): 462-8. treatment reduces long-term mortality						AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-3028	Garnick, D., Horgan, C., & Chalk, M. 2006. Performance measures for alcohol and other drug services. Alcohol Research & Health, 29(1), 19-26 Retrieved from https://pubs.niaaa.nih.gov/publications/arh291/19-26.htm for Alcohol and Other Drug Services						AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3029	Duffy, P., Baldwin, H. 2013. Recovery post treatment: plans, barriers and motivators, Substance Abuse Treatment, Prevention, and Policy, 8:1, 6.						AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3030	Scheier LM and Grenard JL. 2010. Influence of a nationwide social marketing campaign on adolescent drug use, Journal of Health Communication, 12(3) 240-271						AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3031	Madras BK. 2010, Feb. Office of National Drug Control Policy: a scientist in drug policy in Washington, DC. Ann N Y Acad Sci. 1187:370-402						AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3032	Forrest, C.E. 2016. Collateral Consequences of a Criminal Conviction: Impact on Corrections and Reentry. NIJ Update. Corrections Today. American Correctional Association						AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3033	Kortenkamp, K., and Ehrle, J. 2002. The well-being of children involved with the child welfare system: A national overview, New Federalism, Series B, No. B-43. Washington, D.C.: The Urban Institute. http://www.urban.org/UploadedPDF/310413_anf_b43.pdf						AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-3034	Rosenblum, A., et al., 2011. Distance traveled and cross-state commuting to opioid treatment programs in the United States. <i>J Environ Public Health</i> , 2011; p. 948789.					AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3035	Palmgreen, P., Donohew, L, Lorch, EP, Hoyle, RH, & Stephenson, MT. 2001. Television campaigns and adolescent marijuana use: Tests of sensation seeking targeting, <i>American Journal of Public Health</i> , 91, 292-296					AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3036	Newton NC, Champion KE, Slade T, Chapman C, Stapinski L, Koning, Tonks Z, Teesson M. 2017, May. A systematic review of combined student- and parent-based programs to prevent alcohol and other drug use among adolescents. <i>Drug Alcohol Rev.</i> 36(3):337-351					AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3037	CDC. 2016. Morbidity and Mortality Weekly Report (MMWR). Incidence of Neonatal Abstinence Syndrome. Retrieved from https://www.cdc.gov/mmwr/volumes/65/wr/mm6531a2.htm					AU; H; R; PRE; CON; CU; LF; PR/AU; INC; INA; V; PO	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3038	National Quality Forum. 2017. Behavioral Health 2016-2017: final Technical Report. https://www.qualityforum.org/Publications/2017/08/Behavioral_Health_2016-2017_Final_Report.aspx					AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3039	MacArthur, G. J., Minozzi, S., Martin, N., Vickerman, P., Deren, S., Bruneau, J.,... Hickman, M. 2012. Opiate substitution treatment and HIV transmission in people who inject drugs: Systematic review and meta-analysis. <i>BMJ</i> , 345, e5945					AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-3040	NIDA (2016). Principles of Substance Abuse Prevention for Early Childhood. Retrieved from https://www.drugabuse.gov/publications/principles-substance-abuse-prevention-early-childhood on 2017, September 6.						AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3041	Sullum, J., How Many Daily Heroin Users Are There In The U.S.? Somewhere Between 60,000 And 1 Million. Maybe., Forbes, March 10, 2014						AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3042	Lipari, R.N. and Hughes, A. How people obtain the prescription pain relievers they misuse. The CBHSQ Report: January 12, 2017. Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration, Rockville, MD.						AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3043	Farrelly, MC, Niederdeppe, J, & Yarsevich, J. 2003. Youth tobacco prevention mass media campaigns: Past, present, and future directions, BMJ: TC, Accessed at: http://tobaccocontrol.bmj.com/content/12/suppl_1/135						AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3044	Das, JK, et al. 2016. Interventions for adolescent substance abuse: An overview of systematic reviews, Journal of Adolescent Health, 59: s61-75.						AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3045	Mattick, R.P., et al. 2014. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev (2): p. Cd002207						AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-3046	Guy, GP, Zhang, K, Bohm, MK, Losby, J, Lewis, B, Young, R, Murphy, LB, & Dowell, D. 2017. Vital signs: Changes in opioid prescribing in the United States, 2006-2015. Morbidity and Mortality Weekly (MMWR). 66(26); 697-704					AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3047	Massey J, Kilkenny M, Batdorf S, Sanders SK, Ellison D, Halpin J, Gladden RM, Bixler D, Haddy L, Gupta R. 2017, Sep 22. Opioid Overdose Outbreak - West Virginia, August 2016. MMWR Morb Mortal Wkly Rep. 66(37):975-980					AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3048	National Survey of American Attitudes on Substance Abuse XVI: Teens and Parents; National Center on Addiction and Substance Abuse at Columbia University; August 2011.					PRE; CON; CU; AU; H; R; LF; PR/AU; INC; INA; V; PO	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3049	Bradshaw, C. P., Zmuda, J. H., Kellam, S. G., & Jalongo, N. S. 2009. Longitudinal impact of two universal preventive interventions in first grade on educational outcomes in high school. Journal of Educational Psychology 101(4), 926-937					PRE; CON; CU; H; R; AU; LF; PR/AU; INC; INA; V; PO	12 O.S. 2401, 2402; 12 O.S. 2802
S-3050	Woody, G. E., Bruce, D., Korthis, P. T., Chhatre, S., Poole, S., Hillhouse, M., ...Ling, W. 2014. HIV risk reduction with buprenorphine-naloxone or methadone: Findings from a randomized trial. Journal of Acquired Immune Deficiency Syndromes, 66(3), 288-293					H; R; PRE; CON; CU; AU; LF; PR/AU; INC; INA; V; PO	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2802

S-3051	Cummings JR, Wen H, Ko M, and Druss BG. 2014. Race/Ethnicity and Geographic Access to Medicaid Substance Use Disorder Treatment Facilities in the United States. JAMA Psychiatry 71(2):190-196							H; R; PRE; AU; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2802
S-3052	Madras BK, Compton WM, Avula D, Stegbauer T, Stein JB, Clark HW. 2009, Jan 1. Screening, brief interventions, referral to treatment (SBIRT) for illicit drug and alcohol use at multiple healthcare sites: comparison at intake and 6 months later. Drug Alcohol Depend. 99(1-3):280-95							H; R; PRE; AU; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2802
S-3053	Schwartz, R. P., Jaffe, J. H., O'Grady, K. E., Kinlock, T. W., Gordon, M. S., Kelly, S. M., Ahmed, A. 2009. Interim methadone treatment: Impact on arrests. Drug and Alcohol Dependence, 103(3), 148-154.							H; R; PRE; AU; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2802
S-3054	Glasner-Edwards, S., Rawson, R. 2010. Evidence-based practices in addiction treatment: Review and recommendations for public policy. Health Policy. 97. 93-104							H; R; PRE; AU; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2802
S-3055	Kuklinski, Margaret R., et al. 2012. "Cost-benefit analysis of Communities That Care outcomes at eighth grade." Prevention Science 13.2: 150-161.							PRE; CON; CU; H; R; AU; LF; PR/AU; INC; INA; V; PO	12 O.S. 2401, 2402; 12 O.S. 2802
S-3056	Friedmann PD, Hoskinson R, Jr, Gordon M, Schwartz R, et al. (2012). Medication-Assisted Treatment in criminal justice agencies affiliated with the Criminal Justice-Drug Abuse Treatment Studies (CJ-DATS): Availability, barriers and intentions. Subst Abuse. 33:9-18.							AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-3057	Belenko, S. et al. 2013. Treating Substance Use Disorders in the Criminal Justice System. <i>Curr Psychiatry Rep.</i> 15(11).							H; R; PRE; AU; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2802
S-3058	Pullen E and Oser C. 2014. Barriers to Substance Abuse Treatment in Rural and Urban Communities: Counselor Perspectives. <i>Substance Use and Misuse</i> 49:891-901							H; R; PRE; AU; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2802
S-3059	Gibson, LA, Parvanta, SA, Jeong, M, & Hornik RC. 2014. Evaluation of a mass media campaign promoting using help to quit smoking, <i>American Journal of Preventive Medicine</i> , 4(5): 487-495.							H; R; PRE; AU; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2802
S-3060	Hser YI, Evans E, Huang D, Weiss R, Saxon A, Carroll KM, Woody G, Liu D, Wakim P, Matthews AG, Hatch-Maillette M, Jelstrom E, Wiest K, McLaughlin P, Ling W. 2016, Apr. Long-term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi-site trial. <i>Addiction</i> . 111(4):695-705.							H; R; PRE; AU; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2802
S-3061	Bateman BT, Franklin JM, Bykov K, Avorn J, Shrank WH, Brennan TA, Landon JE, Rathmell JP, Huybrechts KF, Fischer MA, Choudhry NK. 2016 Sep Persistent opioid use following cesarean delivery: patterns and predictors among opioid-naïve women. <i>Am J Obstet Gynecol</i> .215(3):353.e1-353.e18							H; R; PRE; AU; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2802

S-3062	Walsh SL, Nuzzo PA, Babalonis S, Casselton V, Lofwall MR. 2016, May 1. Intranasal buprenorphine alone and in combination with naloxone: Abuse liability and reinforcing efficacy in physically dependent opioid abusers. Drug Alcohol Depend. 162:190-8					H; R; PRE; AU; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2802
S-3063	Jena AB1, Goldman DZ, Karaca-Mandic P3. 2016, Jul 1. Hospital Prescribing of Opioids to Medicare Beneficiaries JAMA Intern Med. 176(7):990-7. doi: 10.1001/jamainternmed.2016.2737					H; R; PRE; AU; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2802
S-3064	Baker JA, Avorn J, Levin R, Bateman BT. 2016, Apr 19. Opioid Prescribing After Surgical Extraction of Teeth in Medicaid Patients, 2000-2010. JAMA. 315(15):1653-4					H; R; PRE; AU; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2802
S-3065	Wang J, Fang H, Carreiro S, Wang H, Boyer E. 2017, Jan. A New Mining Method to Detect Real Time Substance Use Events from Wearable Biosensor Data Stream. Int Conf Comput Netw Commun. 2017:465-470.					H; R; PRE; AU; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2802
S-3066	Substance Abuse and Mental Health Services Administration. 2017. Results from the 2016 National Survey on Drug Use and Health: Detailed Tables. Table 6.53B. Retrieved from https://www.samhsa.gov/data/sites/default/files/NSDUH-DetTabs-2016.pdf , accessed on October 26, 2017.					H; R; PRE; AU; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2802

S-3067	Center for Behavioral Health Statistics and Quality. 2017. Key substance use and mental health indicators in the United States: Results from the 2016 National Survey on Drug Use and Health (HHS Publication No. SMA 16-166)								H; R; PRE; AU; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2802
S-3068	Kermack, A., et al. 2017. Buprenorphine prescribing practice trends and attitudes among New York providers. J Subst Abuse Treat 74: p. 1-6								R; PRE; CON; CU; H; PRE; AU; LF; PR/AU; INC; INA; V; PO	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2802
S-3069	World Health Organization. 2009. Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. Geneva, Switzerland: WHO Press.								AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3070	Marlowe D, Hardin C, Fox C. 2016. Painting the Current Picture: A National Report on Drug Courts and Other Problem-Solving Courts in the United States, National Drug Court Institute. Alexandria, VA. Retrieved from https://www.ndci.org/wp-content/uploads/2016/05/Painting-the-Current-Picture-2016.pdf								AU; H; R; PRE; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3071	Knight JR, Harris SK, Sherritt L, Van Hook S, Lawrence N, Brooks T, Carey P, Kossack R, Kulig J. 2007, Nov. Prevalence of positive substance abuse screen results among adolescent primary care patients. Arch Pediatr Adolesc Med. 161(11):1035-41								H; R; PRE; AU; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2802
S-3072	Mednick SC, Christakis NA, Fowler JH. 2010 Mar 19. The spread of sleep loss influences drug use in adolescent social networks. PLoS One. 5(3):e9775.								H; R; PRE; AU; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2802

S-3073	Boston Globe and Harvard T.H. Chan School of Public Health. Prescription painkiller abuse: Attitudes among adults in Massachusetts and the United States. May 2015. https://cdn1.sph.harvard.edu/wpcontent/uploads/sites/21/2015/05/Prescription-Painkiller-Poll-Report.pdf .						H; R; PRE; AU; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2802
S-3074	Nam YH, Shea DG, Shi Y, Moran JR. 2017, May. State prescription drug monitoring programs and fatal drug overdoses. Am J Manag Care. 23(5):297-303						H; R; PRE; AU; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2802
S-3075	Ryan SM, Jorm AF, Lubman DI. 2010. Parenting factors associated with reduced adolescent alcohol use: a systematic review of longitudinal studies. Aust N Z J Psychiatry 44:774-783.						H; R; PRE; AU; LF; PR/AU; CON; INC; INA; V; PO; CU	12 O.S. 2401, 2402; 12 O.S. 2802
S-3076	State of Washington Department of Health. WSR-11-12-025. Permanent Rules. Medical Quality Assurance Commission. Retrieved at http://apps.leg.wa.gov/documents/asswsr/wsr/2011/12/11-12-025.htm .						R; PRE; CON; CU; H; PRE; AU; IC; LF; PR/AU; INC; INA; V; PO	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2802
S-3077	What America's Users Spend on Illegal Drugs: 2000-2010, RAND for ONDCP, Feb 2014						H; R; PRE; CON; CU; AU; LF; PR/AU; INC; INA; V; PO	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2802
S-3078	Purdue's Responses and Objections to Plaintiff's First Request for Production and First Set of Interrogatories and any documents relied on and/or cited therein						R; PRE; PO; T-MIL-2; J-MIL-12	
S-3079	Teva and Acquired Actavis Entities' Responses and Objections to First Set of Interrogatories and any documents relied on and/or cited therein						R; PRE; PO; INC; T-MIL-1, 2	

S-3080	Defendants Janssen and Johnson & Johnson's Responses and Objections to Plaintiff's First Set of Interrogatories with Exhibits 1-4 and any documents relied on and/or cited therein					R; PRE; PO; INC; INA; CON; T-MIL-1, 2; H; SUM; J-MIL-4, 12	
S-3081	Purdue's Response to Request for Information Concerning Corporate Structure and any documents relied on and/or cited therein					R; PRE; CON; INA; PO; H; SUM; T-MIL-1, 2, 4; J-MIL-7, 12	
S-3082	Purdue's Supplemental Response to Interrogatory No. 2 and any documents relied on and/or cited therein					R; PRE; CON; INA; PO; H; SUM; T-MIL-1, 2, 4; J-MIL-7, 12	
S-3083	Objections and Responses of Teva Defendants to Plaintiff's First Request for Admissions and any documents relied on and/or cited therein					R; PRE; PO; H; CON; INA; SUM; T-MIL-1, 2; J-MIL-12	
S-3084	Responses and Objections to Plaintiff's Second Set of Interrogatories and any documents relied on and/or cited therein					R; PRE; PO; INC; CON; SUM; T-MIL-1, 2	
S-3085	Responses and Objections to Plaintiff's Second Request for Production of Documents and any documents relied on and/or cited therein					R; PRE; PO; INC; CON; T-MIL-1, 2	
S-3086	Janssen Responses to Plaintiff's Third Set of Interrogatories and any documents relied on and/or cited therein					R; PRE; PO; H; CON; INA; SUM; T-MIL-1, 2; J-MIL-4, 12	
S-3087	Purdue's Responses and Objections to Plaintiff's Second Set of Interrogatories and any documents relied on and/or cited therein					R; PRE; CON; INA; PO; T-MIL-1, 2, 4; J-MIL-7, 12	

S-3088	Teva's Objections and Responses of Defendants Cephalon, Inc. and Teva Pharmaceuticals USA, Inc. to Plaintiff's Second Set of Interrogatories and any documents relied on and/or cited therein							R; PRE; PO; T-MIL-2; J-MIL-12	
S-3089	Defendants Janssen Pharmaceuticals, Inc and Johnson & Johnson's Responses and Objections to Plaintiff's Fourth Set of Interrogatories and any documents relied on and/or cited therein							R; PRE; PO; INC; CON; INA; T-MIL-1, 2	
S-3090	Objections and Responses of Teva Defendants to Plaintiff's Amended Third Set of Interrogatories and any documents relied on and/or cited therein							R; PRE; PO; T-MIL-2, 4; J-MIL-7, 12	
S-3091	Defendants Janssen and Johnson & Johnson's Responses and Objections to Plaintiff's Fifth Set of Interrogatories and any documents relied on and/or cited therein							R; PRE; PO; INC; CON; INA; T-MIL-1, 2	
S-3092	Purdue's Responses and Objections to Plaintiff's Third Set of Interrogatories and any documents relied on and/or cited therein							R; PRE; PO; INA; INC; CON; T-MIL-1, 2, 4; J-MIL-7	
S-3093	Purdue's Responses and Objections to Plaintiff's First Request for Admissions and any documents relied on and/or cited therein							R; PRE; PO; INA; INC; CON; T-MIL-1, 2, 4; J-MIL-7	12 O.S. 2401, 2402
S-3094	Purdue's Responses & Objections to Plaintiff's Interrogatory Propounded During December 14, 2018 Deposition and any documents relied on and/or cited therein							R; PRE; PO; INA; INC; CON; T-MIL-1, 2, 4; J-MIL-7	
S-3095	Janssen's Written Responses to Topics 17 and 43 and any documents relied on and/or cited therein							R; PRE; PO; INC; CON; INA; T-MIL-1, 2	

S-3096	Verification for Purdue's Supplemental ROG Responses to Nos. 3, 4, 7, 9, 14 and any documents relied on and/or cited therein					R; PRE; PO; INA; INC; CON; T-MIL-1, 2, 4; J-MIL-7	
S-3097	Purdue's Supplemental Responses to ROG Nos. 3, 5, 7, 9, 14 and any documents relied on and/or cited therein					R; PRE; PO; T-MIL-1, 2, 4; J-MIL-7	
S-3098	Janssen Supplemental Responses to Interrogatories 3, 5, 7, 9 and any documents relied on and/or cited therein					PO; INA; SUM; H; R; PRE; T-MIL-1, 2; J-MIL-3	
S-3099	Exhibit 1A to Janssen's Supplemental Responses to Interrogatories 3, 5, 7, 9 and any documents relied on and/or cited therein					PO; INA; SUM; H; R; PRE; T-MIL-1, 2; J-MIL-3	
S-3100	Exhibit 2A to Janssen's Supplemental Response to Interrogatories 3, 5, 7, 9 and any documents relied on and/or cited therein					PO; INA; SUM; H; R; PRE; T-MIL-1, 2; J-MIL-3	
S-3101	Exhibit 3A to Janssen's Supplemental Response to Interrogatories 3, 5, 7, 9 and any documents relied on and/or cited therein					PO; INA; SUM; H; R; PRE; T-MIL-1, 2; J-MIL-3	
S-3102	Janssen's Written Response to Topic 42 and any documents relied on and/or cited therein					PO; INA; SUM; H; R; PRE; T-MIL-1, 2	
S-3103	Exhibit A to Janssen's Written Response to Topic 42 and any documents relied on and/or cited therein					PO; INA; SUM; H; R; PRE; T-MIL-1, 2	
S-3104	Janssen's Written Response to Topics 18 and 38 and any documents relied on and/or cited therein					PO; INA; H; R; PRE; T-MIL-1, 2	

S-3105	Appendix to Janssen's Written Response to Topic 18 and any documents relied on and/or cited therein						PO; INA; H; R; PRE; J-MIL-4; T-MIL-1, 2	
S-3106	Janssen's Written Response to Topics 34 and 44 and any documents relied on and/or cited therein						PO; INA; H; R; PRE; J-MIL-4; T-MIL-1, 2	
S-3107	Exhibit A to Janssen's Written Response to Topic 44 and any documents relied on and/or cited therein						PO; INA; H; R; PRE; J-MIL-4; T-MIL-1, 2	
S-3108	Exhibit B to Janssen's Written Response to Topic 44 and any documents relied on and/or cited therein						PO; INA; H; R; PRE; J-MIL-4; T-MIL-1, 2	
S-3109	Purdue's Supplemental Written Responses to 30(b)(6) Topics in MDL No. 2804 and any documents relied on and/or cited therein				POK003736126		AU; H; R; PRE; CON; CU; PO; INA; LF; T-MIL-1, 2, 4; J-MIL-7	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3110	CRIMINAL JUSTICE DAMAGES.SAV				OKEXPRT-000000005		AU; LF; CON; INC; R; PRE; PO; SUM; T-MIL-7	
S-3111	EXCESS MEDICAL DAMAGES.SAV				OKEXPRT-000000006		AU; H; R; LF; CON; INC; PRE; PO; SUM; T-MIL-7	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3112	FOSTER DAMAGES.SAV				OKEXPRT-000000007		AU; H; R; LF; CON; INC; PRE; PO; SUM; T-MIL-7	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3113	TREATMENT DAMAGES.SAV				OKEXPRT-000000008		AU; H; R; LF; CON; INC; PRE; PO; SUM; T-MIL-7	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3114	HC INCARCERATION DAMAGES.SAV				OKEXPRT-000000009		AU; H; R; LF; CON; INC; PRE; PO; SUM; T-MIL-1, 7	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3115	ODD AND DEATHS.SAV				OKEXPRT-000000010		AU; LF; CON; INC; R; PRE; PO; SUM; T-MIL-1, 7	
S-3116	HC REDUCED DAMAGES.SAV				OKEXPRT-000000011		AU; H; R; LF; CON; INC; PRE; PO; SUM; T-MIL-1, 7	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-3117	HC DEATH DAMAGES.SAV	OKEXPRT-00000012	OKEXPRT-00000012			R; PRE; CON; CU; AU; H; PRE; LF; INC; PO; SUM; T-MIL-1, 7	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3118	OKDAM9.SPS	OKEXPRT-00000013	OKEXPRT-00000013			AU; H; R; LF; CON; INC; PRE; PO; SUM; T-MIL-1, 7	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3119	NAS DAMAGES.SAV	OKEXPRT-00000014	OKEXPRT-00000014			AU; H; R; LF; CON; INC; PRE; PO; SUM; T-MIL-1, 7	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3120	FCATOTAL.SPS	OKEXPRT-00000015	OKEXPRT-00000015			AU; H; R; LF; CON; INC; PRE; PO; SUM; T-MIL-7	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3121	FCA FINAL.SAV	OKEXPRT-00000016	OKEXPRT-00000016			AU; H; R; LF; CON; INC; PRE; PO; SUM; T-MIL-7	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3122	REFERENCES version 7, Final.docx	OKEXPRT-00000001	OKEXPRT-00000004			AU; H; R; LF; CON; CU; INC; PRE; PO; SUM; T-MIL-1, 7, 9	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3123	FCA PERIODS.SAV	OKEXPRT-00000017	OKEXPRT-00000017			AU; H; R; LF; CON; INC; PRE; PO; SUM; T-MIL-1, 7, 9	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3124	Birnbaum 2006 Estimated Costs_of_Prescription_Opioid Analgesic.1.pdf	OKEXPRT-00000018	OKEXPRT-00000027			H; R; PRE; AU; LF; CON; INC; INA; V; PO; CU; SUM	12 O.S. 2401, 2402; 12 O.S. 2802
S-3125	Boscarino et al.pdf	OKEXPRT-00000028	OKEXPRT-00000035			H; R; PRE; AU; LF; CON; INC; INA; V; PO; CU; SUM	12 O.S. 2401, 2402; 12 O.S. 2802
S-3126	Patrick et al NAS JAMA 2012.pdf	OKEXPRT-00000036	OKEXPRT-00000042			H; R; PRE; AU; LF; CON; INC; INA; V; PO; CU; SUM	12 O.S. 2401, 2402; 12 O.S. 2802
S-3127	CAM 032414 integrated outcomes and cost analysis DRAFT.docx	OKEXPRT-00000043	OKEXPRT-00000055			AU; H; R; PRE; LF; CON; INC; INA; V; PO; CU; SUM	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3128	NSDUH-DeTlts2014.pdf	OKEXPRT-00000056	OKEXPRT-00002459			R; PRE; CON; CU; H; PRE; AU; LF; INC; PO; SUM; V; T-MIL-1, 7	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2802
S-3129	Ruhm 2017 Supplementary Appendix.pdf	OKEXPRT-00002460	OKEXPRT-00002464			H; R; AU; LF; CON; CU; INC; PRE; PO; SUM; T-MIL-1, 7, 9	12 O.S. 2401, 2402; 12 O.S. 2802
S-3130	Birnbaum et al 2011.pdf	OKEXPRT-00002465	OKEXPRT-00002475			First Amendment; AU; H; R; PRE; LF; CON; INC; INA; V; PO; CU; SUM	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3131	Florence et al 2016.pdf	OKEXPRT-00002476	OKEXPRT-00002481			H; R; PRE; AU; LF; CON; INC; INA; V; PO; CU; SUM	12 O.S. 2401, 2402; 12 O.S. 2802

S-3132	Ruum, Geographic Variation.pdf	OKEXPRT-00002482	OKEXPRT-00002490			H; R; PRE; AU; LF; CON; INC; INA; V; PO; CU; SUM	12 O.S. 2401, 2402; 12 O.S. 2802
S-3133	MLR_2016_08_01_FLORENCE_MDC- D-16-00101_SDC1(2).xlsx	OKEXPRT-00002491	OKEXPRT-00002491			AU; H; R; LF; CON; CU; INC; PRE; PO; SUM; V; T-MIL-1, 7, 9	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3134	CEA, The Underestimated Cost of the Opioid Crisis.pdf	OKEXPRT-00002492	OKEXPRT-00002505			H; R; AU; LF; CON; CU; INC; PRE; PO; SUM; V; T-MIL-1, 7, 9	12 O.S. 2401, 2402; 12 O.S. 2802
S-3135	Ruhm 2018 add14144-sup-0001- appendix1.docx	OKEXPRT-00002506	OKEXPRT-00002521			AU; H; R; LF; CON; CU; INC; PRE; PO; SUM; V; T-MIL-1, 7, 9	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3136	Grosse et al 2009 Economic Productivity.pdf	OKEXPRT-00002522	OKEXPRT-00002532			H; R; AU; LF; CON; CU; INC; PRE; PO; SUM; V; T-MIL-1, 7, 9	12 O.S. 2401, 2402; 12 O.S. 2802
S-3137	MLR_2016_08_01_FLORENCE_MDC- D-16-00101_SDC2.docx	OKEXPRT-00002533	OKEXPRT-00002555			AU; H; R; LF; CON; CU; INC; PRE; PO; SUM; V; T-MIL-1, 7, 9	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3138	Kolodny annurev-publhealth-031914- 122957 (002).pdf	OKEXPRT-00002556	OKEXPRT-00002577			H; R; AU; LF; CON; CU; INC; PRE; PO; SUM; V; T-MIL-1, 7, 9	12 O.S. 2401, 2402; 12 O.S. 2802
S-3139	Ruhm 2018 CorrectedOpioidInvolvedDeaths.pdf	OKEXPRT-00002578	OKEXPRT-00002583			H; R; AU; LF; CON; CU; INC; PRE; PO; SUM; V; T-MIL-1, 7, 9	12 O.S. 2401, 2402; 12 O.S. 2802
S-3140	Barocas et al 2018 Mass OUD Prevalence Study.pdf	OKEXPRT-00002584	OKEXPRT-00002590			R; PRE; CON; CU; H; PRE; AU; LF; INC; PO; SUM; V; T-MIL-1, 7, 9	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2802
S-3141	Commentary on "The economic burden of prescription opioid overdose, abuse, and.pdf	OKEXPRT-00002591	OKEXPRT-00002594			AU; H; R; LF; CON; CU; INC; PRE; PO; SUM; V; T-MIL-1, 7, 9	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3142	Patrick et al NAS J Perin 2015.pdf	OKEXPRT-00002595	OKEXPRT-00002608			H; R; AU; LF; CON; CU; INC; PRE; PO; SUM; V; T-MIL-1, 7, 9	12 O.S. 2401, 2402; 12 O.S. 2802
S-3143	RTI 2018 National Survey on Drug Use and Health (NSDUH) RTI.pdf	OKEXPRT-00002609	OKEXPRT-00002613			R; PRE; CON; CU; AU; H; PRE; LF; INC; PO; SUM; V; T-MIL-1, 9	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3144	National Survey on Drug Use and Health 2018.pdf	OKEXPRT-00002614	OKEXPRT-00002616			H; R; AU; LF; CON; CU; INC; PRE; PO; SUM; V; T-MIL-1, 9	12 O.S. 2401, 2402; 12 O.S. 2802
S-3145	NAS Data.pdf	OKEXPRT-00002617	OKEXPRT-00002618			AU; H; R; LF; CON; CU; INC; PRE; PO; SUM; V; T-MIL-1, 7, 9	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3146	NSDUH 2014, PART 1.pdf	OKEXPRT-00002619	OKEXPRT-00002622			AU; H; R; LF; CON; CU; INC; PRE; PO; SUM; V; T-MIL-1, 7, 9	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3147	NSDUH 2014, PART 2.pdf	OKEXPRT-00002623	OKEXPRT-00002626			AU; H; R; LF; CON; CU; INC; PRE; PO; SUM; V; T-MIL-1, 7, 9	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-3148	substance abuse removals.pdf	OKEXPRT-00002627	OKEXPRT-00002627	OKEXPRT-00002627		AU; H; R; LF; CON; CU; INC; PRE; PO; SUM; V; T-MIL-1, 7, 9	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3149	NSDUHresults2007.pdf	OKEXPRT-00002628	OKEXPRT-00002628	OKEXPRT-00002933		H; R; AU; LF; CON; CU; INC; PRE; PO; SUM; V; T-MIL-1, 7, 9	12 O.S. 2401, 2402; 12 O.S. 2802
S-3150	NSDUHresults2013.pdf	OKEXPRT-00002934	OKEXPRT-00002934	OKEXPRT-00003117		H; R; AU; LF; CON; CU; INC; PRE; PO; SUM; V; T-MIL-1, 7, 9	12 O.S. 2401, 2402; 12 O.S. 2802
S-3151	NSDUHresults2012.pdf	OKEXPRT-00003118	OKEXPRT-00003118	OKEXPRT-00003295		H; R; AU; LF; CON; CU; INC; PRE; PO; SUM; V; T-MIL-1, 7, 9	12 O.S. 2401, 2402; 12 O.S. 2802
S-3152	National Findings 2002.pdf	OKEXPRT-00003296	OKEXPRT-00003296	OKEXPRT-00003569		AU; H; R; LF; CON; CU; INC; PRE; PO; SUM; V; T-MIL-1, 7, 9	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3153	National Findings 2004.pdf	OKEXPRT-00003570	OKEXPRT-00003570	OKEXPRT-00003879		H; R; AU; LF; CON; CU; INC; PRE; PO; SUM; V; T-MIL-1, 9	12 O.S. 2401, 2402; 12 O.S. 2802
S-3154	National Findings 2005.pdf	OKEXPRT-00003880	OKEXPRT-00003880	OKEXPRT-00004163		H; R; AU; LF; CON; CU; INC; PRE; PO; SUM; V; T-MIL-1, 9	12 O.S. 2401, 2402; 12 O.S. 2802
S-3155	National Findings 2006.pdf	OKEXPRT-00004164	OKEXPRT-00004164	OKEXPRT-00004445		H; R; AU; LF; CON; CU; INC; PRE; PO; SUM; V; T-MIL-1, 9	12 O.S. 2401, 2402; 12 O.S. 2802
S-3156	National Findings 2007.pdf	OKEXPRT-00004446	OKEXPRT-00004446	OKEXPRT-00004751		H; R; AU; LF; CON; CU; INC; PRE; PO; SUM; V; T-MIL-1, 9	12 O.S. 2401, 2402; 12 O.S. 2802
S-3157	National Findings 2008.pdf	OKEXPRT-00004752	OKEXPRT-00004752	OKEXPRT-00005055		H; R; AU; LF; CON; CU; INC; PRE; PO; SUM; V; T-MIL-1, 9	12 O.S. 2401, 2402; 12 O.S. 2802
S-3158	National Findings 2009.pdf	OKEXPRT-00005056	OKEXPRT-00005056	OKEXPRT-00005159		H; R; AU; LF; CON; CU; INC; PRE; PO; SUM; V; T-MIL-1, 9	12 O.S. 2401, 2402; 12 O.S. 2802
S-3159	National Findings 2011.pdf	OKEXPRT-00005160	OKEXPRT-00005160	OKEXPRT-00005333		H; R; AU; LF; CON; CU; INC; PRE; PO; SUM; V; T-MIL-1, 9	12 O.S. 2401, 2402; 12 O.S. 2802
S-3160	National Findings 2012.pdf	OKEXPRT-00005334	OKEXPRT-00005334	OKEXPRT-00005511		H; R; AU; LF; CON; CU; INC; PRE; PO; SUM; V; T-MIL-1, 9	12 O.S. 2401, 2402; 12 O.S. 2802
S-3161	National Findings 2013.pdf	OKEXPRT-00005512	OKEXPRT-00005512	OKEXPRT-00005695		H; R; AU; LF; CON; CU; INC; PRE; PO; SUM; V; T-MIL-1, 9	12 O.S. 2401, 2402; 12 O.S. 2802
S-3162	Results of the 2013 NSDUH_ Detailed Tables, SAMHSA, CBHSQ.html	OKEXPRT-00005696	OKEXPRT-00005696	OKEXPRT-00005696		R; PRE; CON; CU; PRE; AU; LF; INC; H; PO; SUM; V; T-MIL-1, 7, 9	12 O.S. 2401, 2402; 12 O.S. 2403
S-3163	Crews.Morphine.abuse.1990.pdf	OKEXPRT-00005697	OKEXPRT-00005697	OKEXPRT-00005700		Judicial Estoppel; R; PRE; CON; CU; AU; H; R; LF; INC; PRE; PO; SUM; V; T-MIL-1, 9	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3164	Purdue.CMAJ.art.1998.pdf	OKEXPRT-00005701	OKEXPRT-00005701	OKEXPRT-00005701		H; R; AU; LF; CON; CU; INC; PRE; PO; SUM; V; T-MIL-1, 9	12 O.S. 2401, 2402; 12 O.S. 2802
S-3165	Purdue.CMAJ.article.1998.pdf	OKEXPRT-00005702	OKEXPRT-00005702	OKEXPRT-00005705		H; R; AU; LF; CON; CU; INC; PRE; PO; SUM; V; T-MIL-1, 9	12 O.S. 2401, 2402; 12 O.S. 2802

S-3166	Purdue.CMAJ.Goldman.art.1998.pdf	OKEXPERT-00005706	OKEXPERT-00005707		AU; H; R; LF; CON; CU; INC; PRE; PO; SUM; V; T-MIL-1, 9	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3167	1-76 from Documents-Ruhm[1].pdf	OKEXPERT-00005708	OKEXPERT-00005783		AU; H; R; LF; CON; CU; INC; PRE; PO; SUM; V; T-MIL-1, 9	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3168	IMG_1681.jpg	OKEXPERT-00005784	OKEXPERT-00005784		AU; R; LF; CON; CU; INC; H; PRE; PO; SUM; V; T-MIL-1, 4	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901
S-3169	IMG_1682.jpg	OKEXPERT-00005785	OKEXPERT-00005785		AU; R; LF; CON; CU; INC; H; PRE; PO; SUM; V; T-MIL-1, 4	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901
S-3170	IMG_1684.jpg	OKEXPERT-00005786	OKEXPERT-00005786		AU; H; R; LF; CON; CU; INC; PRE; PO; SUM; V; T-MIL-1, 4	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3171	IMG_1686.jpg	OKEXPERT-00005787	OKEXPERT-00005787		AU; R; LF; CON; CU; INC; H; PRE; PO; SUM; V; T-MIL-1, 4	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901
S-3172	12-Common Myths about Prescribing Opioids.flv	OKEXPERT-00005788	OKEXPERT-00005788		AU; H; R; PRE; CON; CU; LF; INC; PO; SUM; V; T-MIL-1, 4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3173	Passik & Portenoy Clips.m4v	OKEXPERT-00005789	OKEXPERT-00005789		AU; H; R; PRE; CON; CU; LF; INC; PO; SUM; V; T-MIL-1, 8, 9	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3174	Portenoy Good Morning America.mp4	OKEXPERT-00005790	OKEXPERT-00005790		AU; H; R; PRE; CON; CU; LF; INC; PO; SUM; V; T-MIL-1, 8, 9	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3175	PORTENOY INTERVIEW.m4v	OKEXPERT-00005791	OKEXPERT-00005791		AU; H; R; PRE; CON; CU; LF; INC; PO; SUM; V; T-MIL-1, 8, 9	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3176	ActavisElizabethLLC.pdf	OKEXPERT-00005792	OKEXPERT-00005796		AU; H; R; LF; PR(AU); PO; CON; INA; PRE; T-MIL-1, 5.	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3177	mm6418 (1).pdf	OKEXPERT-00005797	OKEXPERT-00005824		R; PRE; CON; CU; H; PRE; AU; LF; INC; PO; SUM; V; T-MIL-1, 9	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2802
S-3178	DOHMH_SI public health detailing_AUPH_2016 (1) (1).pdf	OKEXPERT-00005825	OKEXPERT-00005833		R; PRE; CON; CU; H; PRE; AU; LF; INC; PO; SUM; V; T-MIL-1, 9	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2802
S-3179	BI Dept Pain 10th Anniversary.pdf	OKEXPERT-00005834	OKEXPERT-00005839		AU; H; R; LF; CON; CU; INC; PRE; PO; SUM; V; T-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3180	APF Funders and Board 2009.pdf	OKEXPERT-00005840	OKEXPERT-00005840		First Amendment; AU; H; R; LF; CON; IC; CU; INC; PRE; PO; SUM; V	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-3181	Fauber April 2011 UW a force in pain drug growth .pdf	OKEXPERT-00005841	OKEXPERT-00005847		First Amendment; R; PRE; CON; CU; AU; H; R; PRE; LF; IC; INC; PO; SUM; V	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3182	Fauber June 2014 IOM and COI-Painful Disclosures? Medpage Today.pdf	OKEXPERT-00005848	OKEXPERT-00005853		H; R; AU; LF; CON; IC; CU; INC; PRE; PO; SUM; V	12 O.S. 2401, 2402; 12 O.S. 2802
S-3183	Fauber May 2012 Narcotics use for chronic pain soars among seniors.pdf	OKEXPERT-00005854	OKEXPERT-00005865		Nuisance Statute's Safe-harbor; Preemption; H; R; AU; LF; CON; IC; CU; INC; PRE; PO; SUM; V	12 O.S. 2401, 2402; 12 O.S. 2802
S-3184	Fauber Feb 2012 Painkiller boom fueled by networking.pdf	OKEXPERT-00005866	OKEXPERT-00005876		H; R; AU; LF; CON; IC; CU; INC; PRE; PO; SUM; V	12 O.S. 2401, 2402; 12 O.S. 2802
S-3185	Ornstein December 2011 Patient advocacy group funded by success...ugs, probe finds - The Washington	OKEXPERT-00005877	OKEXPERT-00005882		First Amendment; Nuisance Statute's Safe-harbor; Preemption; H; R; PRE; CON; CU; AU; LF; IC; INC; PO; SUM; V	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2802
S-3186	AP CPI Pro-painkiller lobbying drowned out fig...sing drug epidemic The Seattle Times.pdf	OKEXPERT-00005883	OKEXPERT-00005892		First Amendment; H; R; AU; LF; CON; IC; CU; INC; PRE; PO; SUM; V	12 O.S. 2401, 2402; 12 O.S. 2802
S-3187	AP CPI Politics of pain- Drugmakers fought sta...d crisis - Center for Public Integrity.pdf	OKEXPERT-00005893	OKEXPERT-00005903		First Amendment; Judicial Estoppel; R; PRE; CON; CU; H; R; PRE; AU; LF; IC; INC; PO; SUM; V	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2802
S-3188	Giron August 2013 OxyContin maker closely guards its list of suspect doctors - latimes.pdf	OKEXPERT-00005904	OKEXPERT-00005906		H; R; AU; LF; CON; IC; CU; INC; PRE; PO; SUM; V	12 O.S. 2401, 2402; 12 O.S. 2802
S-3189	BI Dept Pain 10th Anniversary.pdf	OKEXPERT-00005907	OKEXPERT-00005912		AU; H; R; LF; CON; CU; INC; PRE; PO; SUM; V; T-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3190	pain_reporter_volume_1_number_2.pdf	OKEXPERT-00005913	OKEXPERT-00005940		First Amendment; H; R; PRE; AU; LF; PR/AU; CON; INA; V; PO; CU; SUM	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3191	Cephalon Video with S.Fishman.pdf	OKEXPERT-00005941	OKEXPERT-00005942		AU; H; R; PRE; LF; PR/AU; CON; INA; V; PO; CU; SUM	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3192	Politics of Pain Texas Summit 2007.pdf	OKEXPERT-00005943	OKEXPERT-00005993		R; PRE; CON; CU; AU; H; PRE; LF; PR/AU; INA; V; PO; SUM	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3193	APF - Treatment Options_A Guide for People Living with Pain.pdf	OKEXPERT-00005994	OKEXPERT-00006002		First Amendment; AU; H; R; PRE; LF; PR/AU; CON; INA; V; PO; CU; SUM	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-3194	Ready for REMS - A Patient's Guide.pdf	OKEXPRT-00006003	OKEXPRT-00006010		AU; H; R; PR/AU; PO; SUM; LF.	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3195	BI Dept Pain 10th Anniversary.pdf	OKEXPRT-00006011	OKEXPRT-00006016		AU; H; R; LF; CON; CU; INC; PRE; PO; SUM; V; T-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3196	APF - Treatment Options, A Guide for People Living with Pain (Full and Clean Copy).pdf	OKEXPRT-00006017	OKEXPRT-00006100		First Amendment; Inadmissible Character Evidence; R; PRE; CON; CU; AU; H; R; PRE; LF; PR/AU; INA; V; PO; SUM	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3197	Pain View I CME July 2 2010.pdf	OKEXPRT-00006101	OKEXPRT-00006103		First Amendment; AU; H; R; LF; PR/AU; PO; CON; INC; IC; INA; 2701; PRE; T-MIL-1, 9	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3198	APF Funders and Board 2009.pdf	OKEXPRT-00006104	OKEXPRT-00006104		First Amendment; AU; H; R; LF; CON; IC; CU; INC; PRE; PO; SUM; V	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3199	PPSG Article on NonMedical Use 2009.pdf	OKEXPRT-00006105	OKEXPRT-00006116		First Amendment; H; R; AU; LF; CON; IC; CU; PRE; PO; SUM; V; INA	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3200	Fishman CMEs.pdf	OKEXPRT-00006117	OKEXPRT-00006122		First Amendment; AU; H; R; LF; CON; IC; INC; CU; PRE; PO; SUM; V	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3201	20180802Mallinckrodt_Pharmaceuticals.pdf	OKEXPRT-00006123	OKEXPRT-00006129		H; R; PRE; CON; CU; AU; LF; PO; SUM; V; INA; T-MIL-1, 4; J-MIL-12	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2802
S-3202	ACCME Complaint June 11 2012.pdf	OKEXPRT-00006130	OKEXPRT-00006141		First Amendment; Judicial Estoppel; Nuisance Statute's Safe-harbor; Preemption; R; PRE; CON; CU; AU; H; R; LF; PRE; PO; SUM; V; T-MIL-1, 4; J-MIL-1, 3, 7, 12	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3203	Opioid Monograph 2007 Final.pdf	OKEXPRT-00006142	OKEXPRT-00006157		R; PRE; CON; CU; AU; H; PRE; LF; PO; SUM; V; T-MIL-1; J-MIL-1, 3, 12	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3204	Nuomorpham.pdf	OKEXPRT-00006158	OKEXPRT-00006158		AU; H; R; LF; CON; INC; IC; INA; PRE; V; T-MIL-1; J-MIL-1, 12	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3205	Endo CME August 29 2010.pdf	OKEXPRT-00006159	OKEXPRT-00006169		First Amendment; AU; H; R; LF; CON; IC; INC; CU; PRE; PO; SUM; V	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-3206	Persistent Pain Older Adult CME.pdf	OKEXPRT-00006170	OKEXPRT-00006200		First Amendment; AU; H; R; LF; CON; IC; INC; CU; PRE; PO; SUM; V	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3207	Endo CME February 2007.pdf	OKEXPRT-00006201	OKEXPRT-00006212		AU; H; R; LF; CON; IC; INC; CU; PRE; PO; SUM; V	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3208	Politics of Pain Texas Summit 2007.pdf	OKEXPRT-00006213	OKEXPRT-00006263		First Amendment; R; PRE; CON; CU; AU; H; R; PRE; LF; PR/AU; INA; V; PO; SUM	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3209	Clinical Tools and Risk Management Strategies CME December 2009.pdf	OKEXPRT-00006264	OKEXPRT-00006291		First Amendment; Judicial Estoppel; R; PRE; CON; CU; AU; H; LF; IC; INC; R; PRE; PO; SUM; V	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3210	BI Dept Pain 10th Anniversary.pdf	OKEXPRT-00006292	OKEXPRT-00006297		AU; H; R; LF; CON; CU; INC; PRE; PO; SUM; V; T-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3211	Pain Management Today Newsletter Issue 8.pdf	OKEXPRT-00006298	OKEXPRT-00006303		First Amendment; Nuisance Statute's Safe-harbor; Preemption; AU; H; R; LF; CON; CU; INC; PRE; PO; SUM; V; T-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3212	APF Funders and Board 2009.pdf	OKEXPRT-00006304	OKEXPRT-00006304		First Amendment; AU; H; R; LF; CON; IC; CU; INC; PRE; PO; SUM; V	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3213	ACP Health Tips 2007 - Spanish.pdf	OKEXPRT-00006305	OKEXPRT-00006306		First Amendment; AU; H; R; PR/AU; PO; CON; CU; INC; IC; INA; LF; PRE	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3214	Fishman CMEs.pdf	OKEXPRT-00006307	OKEXPRT-00006312		AU; H; R; LF; CON; IC; INC; CU; PRE; PO; SUM; V	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3215	ACP Health Tips 2007.pdf	OKEXPRT-00006313	OKEXPRT-00006314		First Amendment; AU; H; R; PR/AU; PO; CON; CU; INC; IC; INA; LF; PRE	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3216	aapmngt 2006 agenda ENDO.png	OKEXPRT-00006315	OKEXPRT-00006315		First Amendment; AU; H; R; LF; CON; IC; INC; CU; PRE; PO; SUM; V	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3217	AAPM 2006 CD-ROM - Handouts.pdf	OKEXPRT-00006316	OKEXPRT-00006319		AU; H; R; LF; CON; IC; INC; CU; PRE; PO; SUM; V	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3218	ActavisElizabethLLC.pdf	OKEXPRT-00006320	OKEXPRT-00006324		H; R; AU; LF; PR/AU; PO; CON; INA; PRE; T-MIL-1, 5.	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-3219	FDA Rappaport Memo in ACTION April 6 2012..pdf	OKEXPERT-00006325	OKEXPERT-00006326		H; R; AU; PR/AU; PO; IC; INA; 2701; LF; PRE; V; T-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2802
S-3220	FDA Response to Prop Petition 2013..pdf	OKEXPERT-00006327	OKEXPERT-00006344		First Amendment; Nuisance Statute's Safe-harbor; Preemption; H; R; AU; PR/AU; PO; IC; INA; 2701; LF; PRE; V; T-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2802
S-3221	FDA REMS Meeting Agenda 2010..pdf	OKEXPERT-00006345	OKEXPERT-00006358		H; R; AU; PR/AU; PO; IC; INA; 2701; LF; PRE; V; CON	12 O.S. 2401, 2402; 12 O.S. 2802
S-3222	FDA REMS Workgroup on Prescriber Ed 2010..pdf	OKEXPERT-00006359	OKEXPERT-00006372		H; R; AU; PR/AU; PO; IC; INA; 2701; LF; PRE; V; SUM	12 O.S. 2401, 2402; 12 O.S. 2802
S-3223	FDA Slides for Pain Care Forum June 14 2012..pdf	OKEXPERT-00006373	OKEXPERT-00006396		H; R; AU; PR/AU; PO; CU; IC; INA; 2701; LF; PRE; SUM	12 O.S. 2401, 2402; 12 O.S. 2802
S-3224	R Gallagher PPT 2009 and Other PPTs REMS 2010..pdf	OKEXPERT-00006397	OKEXPERT-00006463		AU; H; R; PRE; CON; CU; PR/AU; PO; IC; INA; 2701; LF; SUM	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3225	Speeches by FDA Officials > Prescriptio... Issues- FDA Briefing for Stakeholders..pdf	OKEXPERT-00006464	OKEXPERT-00006468		H; R; AU; PR/AU; PO; CU; IC; INA; 2701; LF; PRE; SUM	12 O.S. 2401, 2402; 12 O.S. 2802
S-3226	Speeches by FDA Officials > 2013 National Rx Drug Abuse Summit..pdf	OKEXPERT-00006469	OKEXPERT-00006472		First Amendment; AU; H; R; PR/AU; PO; CU; IC; INA; 2701; LF; PRE; SUM	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3227	Speeches by FDA Officials > Regulating ...g to the National Rx Drug Abuse Summit..pdf	OKEXPERT-00006473	OKEXPERT-00006477		H; R; AU; PR/AU; PO; CU; IC; INA; 2701; LF; PRE; SUM	12 O.S. 2401, 2402; 12 O.S. 2802
S-3228	REMS Briefing Materials July 2010 ERLA REMS..pdf	OKEXPERT-00006478	OKEXPERT-00006851		AU; H; PR/AU; PO; CU; IC; INA; 2701; LF; R; PRE; SUM	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3229	Knox Todd REMS meeting waiver 2010..pdf	OKEXPERT-00006852	OKEXPERT-00006855		AU; H; R; PR/AU; PO; CU; IC; INA; 2701; LF; PRE; SUM	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3230	ERLA REMS 2010 Meeting Agenda .pdf	OKEXPERT-00006856	OKEXPERT-00006860		AU; H; R; PR/AU; PO; IC; INA; 2701; LF; PRE; V; SUM	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3231	DraftMeetingRoster 2010 REMS..pdf	OKEXPERT-00006861	OKEXPERT-00006865		H; R; AU; PR/AU; PO; IC; INA; 2701; LF; PRE; V; SUM	12 O.S. 2401, 2402; 12 O.S. 2802
S-3232	20100722-23-ALSDAC-DSaRM-A1- FinalAgenda..pdf	OKEXPERT-00006866	OKEXPERT-00006870		AU; H; R; PR/AU; PO; IC; INA; 2701; LF; PRE; V; SUM	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3233	20100722-23-ALSDAC-DSaRM-S1-02- Guest-CoreSlides..pdf	OKEXPERT-00006871	OKEXPERT-00007066		AU; H; R; PRE; CON; CU; PR/AU; PO; IC; INA; 2701; LF; SUM	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-3234	20100722-23-ALSDAC-DSaRM-S1-03- IWG-CoreSlides.pdf	OKEXPERT-00007067	OKEXPERT-00007112		First Amendment; AU; H; R; PR/AU; PO; INA; 2701; LF; PRE; V; SUM; CON	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3235	20100722-23-ALSDAC-DSaRM-S1-04- Covidien-CoreSlides.pdf	OKEXPERT-00007113	OKEXPERT-00007122		AU; H; R; PR/AU; PO; INA; 2701; LF; PRE; V; SUM; CON	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3236	20100722-23-ALSDAC-DSaRM-S1-05- OPH-CoreSlides.pdf	OKEXPERT-00007123	OKEXPERT-00007124		AU; H; R; PR/AU; PO; INA; 2701; LF; PRE; V; SUM; CON	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3237	20100722-23-ALSDAC-DSaRM-S1-01- FDA-CoreSlides.pdf	OKEXPERT-00007125	OKEXPERT-00007279		Nuisance Statute's Safe-harbor; Preemption; H; R; PRE; CON; CU; AU; PR/AU; PO; INA; 2701; LF; SUM; V	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2802
S-3238	20100722-ALSDAC-DSaRM-T1- Transcript.pdf	OKEXPERT-00007280	OKEXPERT-00007641		AU; H; R; PR/AU; PO; CU; INA; 2701; LF; PRE; SUM; V	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3239	20100723-ALSDAC-DSaRM-T2- Transcript.pdf	OKEXPERT-00007642	OKEXPERT-00007963		AU; H; R; PR/AU; PO; CU; INA; 2701; LF; PRE; SUM; V	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3240	20100722-23-ALSDAC-DSaRM-M1- Minutes.pdf	OKEXPERT-00007964	OKEXPERT-00007973		AU; H; R; PR/AU; PO; CU; INA; 2701; LF; PRE; SUM; V	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3241	Joint Statement painrelief.pdf	OKEXPERT-00007974	OKEXPERT-00007974		First Amendment; AU; H; R; PR/AU; PO; CU; INA; 2701; LF; PRE; SUM; V	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3242	2008-annual-meeting-brochure.pdf	OKEXPERT-00007975	OKEXPERT-00008002		First Amendment; AU; H; R; PR/AU; PO; CU; INA; 2701; LF; PRE; SUM; V	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3243	2009-annual-meeting-brochure.pdf	OKEXPERT-00008003	OKEXPERT-00008034		First Amendment; AU; H; R; PR/AU; PO; CU; INA; 2701; LF; PRE; SUM; V	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3244	2010-annual-meeting-brochure.pdf	OKEXPERT-00008035	OKEXPERT-00008058		First Amendment; AU; H; R; PR/AU; PO; CU; INA; 2701; LF; PRE; SUM; V	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3245	2009-annual-meeting-program- book.pdf	OKEXPERT-00008059	OKEXPERT-00008138		First Amendment; AU; H; R; PR/AU; PO; CU; INA; 2701; LF; PRE; SUM; V	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3246	2010-annual-meeting-program- book.pdf	OKEXPERT-00008139	OKEXPERT-00008210		First Amendment; AU; H; R; PR/AU; PO; CU; INA; 2701; LF; PRE; SUM; V	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-3247	2011-annual-meeting-program-book.pdf	OKEXPERT-00008211	OKEXPERT-00008282		First Amendment; AU; H; R; PR/AU; PO; CU; INA; 2701; LF; PRE; SUM; V	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3248	2012-annual-meeting-program-book.pdf	OKEXPERT-00008283	OKEXPERT-00008354		First Amendment; AU; H; R; PR/AU; PO; CU; INA; 2701; LF; PRE; SUM; V	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3249	American_Academy_of_Pain_Medicine (AAPM)_Comment.pdf	OKEXPERT-00008355			AU; PR/AU; PO; CU; IC; H; INA; 2701; LF; R; PRE; SUM	
S-3250	2014-annual-meeting-brochure.pdf	OKEXPERT-00008367	OKEXPERT-00008390		First Amendment; AU; H; R; PR/AU; PO; CU; INA; 2701; LF; PRE; SUM; V	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3251	2012-annual-meeting-brochure.pdf	OKEXPERT-00008391	OKEXPERT-00008414		First Amendment; AU; H; R; PR/AU; PO; CU; INA; 2701; LF; PRE; SUM; V	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3252	2015-annual-meeting-brochure.pdf	OKEXPERT-00008415	OKEXPERT-00008438		First Amendment; AU; H; R; PR/AU; PO; CU; INA; 2701; LF; PRE; SUM; V	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3253	2011-annual-meeting-brochure.pdf	OKEXPERT-00008439	OKEXPERT-00008462		First Amendment; AU; H; R; PR/AU; PO; CU; INA; 2701; LF; PRE; SUM; V	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3254	2013-annual-meeting-brochure.pdf	OKEXPERT-00008463	OKEXPERT-00008487		First Amendment; Inadmissible Character Evidence; R; PRE; CON; CU; AU; H; R; PR/AU; PO; INA; 2701; LF; PRE; SUM; V	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3255	2016-annual-meeting-brochure.pdf	OKEXPERT-00008488	OKEXPERT-00008511		First Amendment; AU; H; R; PR/AU; PO; CU; INA; 2701; LF; PRE; SUM; V	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3256	2017-annual-meeting-brochure.pdf	OKEXPERT-00008512	OKEXPERT-00008531		First Amendment; AU; H; R; PR/AU; PO; CU; INA; 2701; LF; PRE; SUM; V	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3257	AAPM_2012_Highlights_transcript_05.pdf	OKEXPERT-00008532	OKEXPERT-00008532		First Amendment; R; PRE; CON; CU; AU; H; R; PRE; PR/AU; PO; INA; 2701; LF; SUM; V	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3258	Comment_from_American_Academy_of_Pain_Medicine-3.pdf	OKEXPERT-00008533	OKEXPERT-00008534		First Amendment; AU; H; R; PR/AU; PO; CU; INA; 2701; LF; PRE; SUM; V	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3259	AAPM Meeting Feb 2010.pdf	OKEXPERT-00008535	OKEXPERT-00008543		First Amendment; AU; H; R; PR/AU; PO; CU; INA; 2701; LF; PRE; SUM; V	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-3260	AAPM CME September 22 2011.pdf	OKEXPERT-00008544	OKEXPERT-00008588		First Amendment; AU; H; R; PR/AU; PO; CU; INA; 2701; LF; PRE; SUM; IC	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3261	PCC Memo.pdf	OKEXPERT-00008589	OKEXPERT-00008595		First Amendment; AU; H; R; PR/AU; PO; CU; INA; 2701; LF; PRE; SUM; V	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3262	King CME 2011.pdf	OKEXPERT-00008596	OKEXPERT-00008606		First Amendment; AU; H; PR/AU; PO; CU; INA; 2701; LF; R; PRE; SUM; V	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3263	AAPM Amicus Brief June 17 1998.pdf	OKEXPERT-00008607	OKEXPERT-00008627		First Amendment; R; PRE; CON; CU; AU; H; R; PRE; PR/AU; PO; INA; 2701; LF; SUM; V	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3264	2012 AAPM Annual Meeting Attendee List.pdf	OKEXPERT-00008628	OKEXPERT-00008652		First Amendment; AU; H; R; LF; CON; IC; CU; INC; PRE; PO; SUM; V	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3265	Pain Action Initiative.pdf	OKEXPERT-00008653	OKEXPERT-00008654		First Amendment; AU; H; LF; CON; IC; CU; INC; R; PRE; PO; SUM; V	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3266	Definitions Paper Savage at All 2003.pdf	OKEXPERT-00008655	OKEXPERT-00008666		First Amendment; H; R; AU; LF; CON; IC; CU; INC; PRE; PO; SUM; V	12 O.S. 2401, 2402; 12 O.S. 2802
S-3267	Definitions Consensus AAPM AAPS ASAM 2001.pdf	OKEXPERT-00008667	OKEXPERT-00008670		First Amendment; AU; H; LF; CON; IC; CU; INC; R; PRE; PO; SUM; V	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3268	AAPM AAPS Consensus Statement 1996.pdf	OKEXPERT-00008671	OKEXPERT-00008674		First Amendment; AU; H; LF; CON; IC; CU; INC; R; PRE; PO; SUM; V	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3269	Fishman CMEs.pdf	OKEXPERT-00008675	OKEXPERT-00008680		First Amendment; AU; H; LF; CON; IC; INC; CU; R; PRE; PO; SUM; V	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3270	Fishman UC Davis Disclosures.pdf	OKEXPERT-00008681	OKEXPERT-00008684		First Amendment; AU; H; R; LF; CON; IC; CU; INC; PRE; PO; SUM; V	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3271	Cruciani PPT.pdf	OKEXPERT-00008685	OKEXPERT-00008698		First Amendment; AU; H; LF; CON; IC; CU; INC; R; PRE; PO; SUM; V	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-3272	R Gallagher PPT 2009 and Other PPTs REMS 2010.pdf	OKEXPERT-00008699	OKEXPERT-00008765		First Amendment; AU; H; R; PRE; CON; CU; PR/AU; PO; IC; INA; 2701; LF; SUM	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802